ID   1A02_HUMAN              Reviewed;         365 AA.
AC   P01892; O19619; P06338; P10313; P30444; P30445; P30446; P30514;
AC   Q29680; Q29837; Q29899; Q95352; Q95380; Q9TPX8; Q9TPX9; Q9TPY0;
AC   Q9TQH5; Q9TQI3;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   13-AUG-1987, sequence version 1.
DT   28-NOV-2012, entry version 151.
DE   RecName: Full=HLA class I histocompatibility antigen, A-2 alpha chain;
DE   AltName: Full=MHC class I antigen A*2;
DE   Flags: Precursor;
GN   Name=HLA-A; Synonyms=HLAA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE A*02:01).
RX   MEDLINE=85132727; PubMed=2982951;
RA   Koller B.H., Orr H.T.;
RT   "Cloning and complete sequence of an HLA-A2 gene: analysis of two HLA-
RT   A alleles at the nucleotide level.";
RL   J. Immunol. 134:2727-2733(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE (ALLELE A*02:01).
RX   MEDLINE=89122144; PubMed=2914713; DOI=10.1007/BF00395855;
RA   Cianetti L., Testa U., Scotto L., la Valle R., Simeone A., Boccoli G.,
RA   Giannella G., Peschle C., Boncinelli E.;
RT   "Three new class I HLA alleles: structure of mRNAs and alternative
RT   mechanisms of processing.";
RL   Immunogenetics 29:80-91(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE (ALLELE A*02:01).
RX   MEDLINE=90207291; PubMed=2320591; DOI=10.1073/pnas.87.7.2833;
RA   Ennis P.D., Zemmour J., Salter R.D., Parham P.;
RT   "Rapid cloning of HLA-A,B cDNA by using the polymerase chain reaction:
RT   frequency and nature of errors produced in amplification.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:2833-2837(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 91-365.
RX   MEDLINE=86033791; PubMed=3863816;
RA   Davidson W.F., Kress M., Khoury G., Jay G.;
RT   "Comparison of HLA class I gene sequences. Derivation of locus-
RT   specific oligonucleotide probes specific for HLA-A, HLA-B, and HLA-C
RT   genes.";
RL   J. Biol. Chem. 260:13414-13423(1985).
RN   [5]
RP   NUCLEOTIDE SEQUENCE (ALLELES A*02:01; A*02:11 AND A*02:12).
RX   MEDLINE=92269955; PubMed=1317015; DOI=10.1038/357326a0;
RA   Belich M.P., Madrigal J.A., Hildebrand W.H., Zemmour J.,
RA   Williams R.C., Luz R., Petzl-Erler M.L., Parham P.;
RT   "Unusual HLA-B alleles in two tribes of Brazilian Indians.";
RL   Nature 357:326-329(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 39-365 (ALLELE A*02:01).
RX   MEDLINE=85230571; PubMed=3874058;
RA   Krangel M.S.;
RT   "Unusual RNA splicing generates a secreted form of HLA-A2 in a
RT   mutagenized B lymphoblastoid cell line.";
RL   EMBO J. 4:1205-1210(1985).
RN   [7]
RP   PROTEIN SEQUENCE OF 25-295 (ALLELE A*02:01).
RX   MEDLINE=80056745; PubMed=92029; DOI=10.1073/pnas.76.9.4395;
RA   Orr H.T., Lopez de Castro J.A., Parham P., Ploegh H.L.,
RA   Strominger J.L.;
RT   "Comparison of amino acid sequences of two human histocompatibility
RT   antigens, HLA-A2 and HLA-B7: location of putative alloantigenic
RT   sites.";
RL   Proc. Natl. Acad. Sci. U.S.A. 76:4395-4399(1979).
RN   [8]
RP   SEQUENCE REVISION (ALLELE A*02:01).
RX   MEDLINE=82247941; PubMed=6179086; DOI=10.1073/pnas.79.12.3813;
RA   Lopez de Castro J.A., Strominger J.L., Strong D.M., Orr H.T.;
RT   "Structure of crossreactive human histocompatibility antigens HLA-A28
RT   and HLA-A2: possible implications for the generation of HLA
RT   polymorphism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 79:3813-3817(1982).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE A*02:01).
RC   TISSUE=Blood;
RX   MEDLINE=95137784; PubMed=7836067; DOI=10.1016/0198-8859(94)90087-6;
RA   Balas A., Garcia-Sanchez F., Gomez-Reino F., Vicario J.L.;
RT   "HLA class I allele (HLA-A2) expression defect associated with a
RT   mutation in its enhancer B inverted CAT box in two families.";
RL   Hum. Immunol. 41:69-73(1994).
RN   [10]
RP   SEQUENCE REVISION.
RA   Balas A.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE (ALLELE A*02:01).
RA   Cox S.T.;
RT   "Confirmation of HLA-A*0201.";
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-298 (ALLELES A*02:02 AND
RP   A*02:03).
RX   MEDLINE=87306734; PubMed=3497874; DOI=10.1007/BF00365911;
RA   Mattson D.H., Handy D.E., Bradley D.A., Coligan J.E., Cowan E.P.,
RA   Biddison W.E.;
RT   "DNA sequences of the genes that encode the CTL-defined HLA-A2
RT   variants M7 and DK1.";
RL   Immunogenetics 26:190-192(1987).
RN   [13]
RP   NUCLEOTIDE SEQUENCE (ALLELES A*02:03 AND A*02:05).
RX   MEDLINE=87252273; PubMed=3496393;
RA   Holmes N., Ennis P., Wan A.M., Denney D.W., Parham P.;
RT   "Multiple genetic mechanisms have contributed to the generation of the
RT   HLA-A2/A28 family of class I MHC molecules.";
RL   J. Immunol. 139:936-941(1987).
RN   [14]
RP   NUCLEOTIDE SEQUENCE (ALLELES A*02:03 AND A*02:05).
RA   Domena J.D.;
RL   Submitted (NOV-1993) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 9-365 (ALLELE A*02:04).
RX   MEDLINE=92039809; PubMed=1937577; DOI=10.1007/BF00211991;
RA   Castano A.R., Lopez de Castro J.A.;
RT   "Structure of the HLA-A*0204 antigen, found in South American Indians.
RT   Spatial clustering of HLA-A2 subtype polymorphism.";
RL   Immunogenetics 34:281-285(1991).
RN   [16]
RP   NUCLEOTIDE SEQUENCE OF 9-365 (ALLELE A*02:04).
RX   MEDLINE=92269956; PubMed=1589035; DOI=10.1038/357329a0;
RA   Watkins D.I., McAdam S.N., Liu X., Stang C.R., Milford E.L.,
RA   Levine C.G., Garber T.L., Dogon A.L., Lord C.I., Ghim S.H.,
RA   Troup G.M., Hughes A.L., Letvin N.L.;
RT   "New recombinant HLA-B alleles in a tribe of South American
RT   Amerindians indicate rapid evolution of MHC class I loci.";
RL   Nature 357:329-333(1992).
RN   [17]
RP   NUCLEOTIDE SEQUENCE (ALLELE A*02:06).
RX   MEDLINE=89235215; PubMed=2715640;
RA   Parham P., Lawlor D.A., Lomen C.E., Ennis P.D.;
RT   "Diversity and diversification of HLA-A,B,C alleles.";
RL   J. Immunol. 142:3937-3950(1989).
RN   [18]
RP   PARTIAL PROTEIN SEQUENCE (ALLELE A*02:06).
RX   MEDLINE=86305811; PubMed=3489037;
RA   Ezquerra A., Domenech N., van der Poel J., Strominger J.L., Vega M.A.,
RA   Lopez de Castro J.A.;
RT   "Molecular analysis of an HLA-A2 functional variant CLA defined by
RT   cytolytic T lymphocytes.";
RL   J. Immunol. 137:1642-1649(1986).
RN   [19]
RP   PARTIAL PROTEIN SEQUENCE (ALLELE A*02:07).
RX   MEDLINE=88113844; PubMed=2448239; DOI=10.1007/BF00346586;
RA   Domenech N., Ezquerra A., Castano R., Lopez de Castro J.A.;
RT   "Structural analysis of HLA-A2.4 functional variant KNE. Implications
RT   for the mapping of HLA-A2-specific T-cell epitopes.";
RL   Immunogenetics 27:196-202(1988).
RN   [20]
RP   PARTIAL PROTEIN SEQUENCE (ALLELE A*02:08).
RX   MEDLINE=88314183; PubMed=2457548; DOI=10.1007/BF00375853;
RA   Domenech N., Castano R., Goulmy E., Lopez de Castro J.A.;
RT   "Molecular analysis of HLA-A2.4 functional variant KLO: close
RT   structural and evolutionary relatedness to the HLA-A2.2 subtype.";
RL   Immunogenetics 28:143-152(1988).
RN   [21]
RP   PARTIAL PROTEIN SEQUENCE (ALLELE A*02:09).
RX   MEDLINE=88186100; PubMed=3258580; DOI=10.1007/BF00395130;
RA   Castano R., Ezquerra A., Domenech N., Lopez de Castro J.A.;
RT   "An HLA-A2 population variant with structural polymorphism in the
RT   alpha 3 region.";
RL   Immunogenetics 27:345-355(1988).
RN   [22]
RP   NUCLEOTIDE SEQUENCE (ALLELE A*02:10).
RX   MEDLINE=89122133; PubMed=2783680; DOI=10.1007/BF00395859;
RA   Epstein H., Kennedy L., Holmes N.;
RT   "An Oriental HLA-A2 subtype is closely related to a subset of
RT   Caucasoid HLA-A2 alleles.";
RL   Immunogenetics 29:112-116(1989).
RN   [23]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 9-365 (ALLELE A*02:11).
RX   MEDLINE=92218010; PubMed=1559719; DOI=10.1007/BF00189898;
RA   Castano A.R., Lopez de Castro J.A.;
RT   "Structure of the HLA-A*0211 (A2.5) subtype: further evidence for
RT   selection-driven diversification of HLA-A2 antigens.";
RL   Immunogenetics 35:344-346(1992).
RN   [24]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*02:13).
RX   MEDLINE=94222455; PubMed=8168863; DOI=10.1007/BF00189243;
RA   Barber D.F., Fernandez J.M., Lopez de Castro J.A.;
RT   "Primary structure of a new HLA-A2 subtype: HLA-A*0213.";
RL   Immunogenetics 39:378-378(1994).
RN   [25]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*02:16).
RX   MEDLINE=95278976; PubMed=7759139; DOI=10.1007/BF00164000;
RA   Barouch D., Krausa P., Bodmer J., Browning M.J., McMichael A.J.;
RT   "Identification of a novel HLA-A2 subtype, HLA-A*0216.";
RL   Immunogenetics 41:388-388(1995).
RN   [26]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*02:17).
RC   TISSUE=Blood;
RX   MEDLINE=95381236; PubMed=7652742;
RX   DOI=10.1111/j.1399-0039.1995.tb02464.x;
RA   Selvakumar A., Granja C.B., Salazar M., Alosco S.M., Yunis E.J.,
RA   Dupont B.;
RT   "A novel subtype of A2 (A*0217) isolated from the South American
RT   Indian B-cell line AMALA.";
RL   Tissue Antigens 45:343-347(1995).
RN   [27]
RP   NUCLEOTIDE SEQUENCE (ALLELE A*02:18).
RC   TISSUE=Blood;
RA   Kashiwase K., Tokunaga K., Ishikawa Y., Oohashi H., Hashimoto M.,
RA   Akaza T., Tadokoro K., Juji T.;
RT   "A new A2 sequence HLA-A2K from Japanese.";
RL   Submitted (FEB-1996) to the EMBL/GenBank/DDBJ databases.
RN   [28]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*02:20).
RC   TISSUE=Blood;
RX   MEDLINE=97161038; PubMed=9008310;
RX   DOI=10.1111/j.1399-0039.1996.tb02691.x;
RA   Fleischhauer K., Zino E., Mazzi B., Severini G.M., Benazzi E.,
RA   Bordignon C.;
RT   "HLA-A*02 subtype distribution in Caucasians from northern Italy:
RT   identification of A*0220.";
RL   Tissue Antigens 48:673-679(1996).
RN   [29]
RP   NUCLEOTIDE SEQUENCE (ALLELE A*02:21).
RC   TISSUE=Blood;
RA   Szmania S., Baxter-Lowe L.A.;
RT   "Nucleotide sequence of a novel HLA-A2 gene.";
RL   Submitted (APR-1996) to the EMBL/GenBank/DDBJ databases.
RN   [30]
RP   NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*02:31).
RX   MEDLINE=20156437; PubMed=10689125; DOI=10.1016/S0198-8859(99)00155-X;
RA   Ellis J.M., Henson V., Slack R., Ng J., Hartzman R.J., Hurley C.K.;
RT   "Frequencies of HLA-A2 alleles in five U.S. population groups.
RT   Predominance Of A*02011 and identification of HLA-A*0231.";
RL   Hum. Immunol. 61:334-340(2000).
RN   [31]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-298 (ALLELE A*02:34).
RX   MEDLINE=20208581; PubMed=10746792;
RX   DOI=10.1034/j.1399-0039.2000.550212.x;
RA   Moses J.H., Greville W.D., Downes J., McClenahan W., Kennedy A.,
RA   Dunckley H.;
RT   "A new HLA-A*02 allele, A*0234, detected by polymerase chain reaction
RT   using sequence-specific primers (PCR-SSP).";
RL   Tissue Antigens 55:175-177(2000).
RN   [32]
RP   NUCLEOTIDE SEQUENCE OF 26-206 (ALLELES A*02:35; A*02:36 AND A*02:37).
RX   MEDLINE=20309230; PubMed=10852390;
RX   DOI=10.1034/j.1399-0039.2000.550412.x;
RA   Ellis J., Steiner N.K., Kosman C., Henson V., Mitton W., Koester R.,
RA   Ng J., Hartzman R.J., Hurley C.K.;
RT   "Seventeen more novel HLA-A locus alleles.";
RL   Tissue Antigens 55:369-373(2000).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-352 AND SER-356, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-352 AND SER-356, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [35]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-110, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (3.5 ANGSTROMS) OF A*02:01.
RX   MEDLINE=88014204; PubMed=3309677; DOI=10.1038/329506a0;
RA   Bjorkman P.J., Saper M.A., Samraoui B., Bennett W.S., Strominger J.L.,
RA   Wiley D.C.;
RT   "Structure of the human class I histocompatibility antigen, HLA-A2.";
RL   Nature 329:506-512(1987).
RN   [37]
RP   INTERACTION WITH HTLV-1 ACCESSORY PROTEIN P12I.
RX   PubMed=11390610; DOI=10.1128/JVI.75.13.6086-6094.2001;
RA   Johnson J.M., Nicot C., Fullen J., Ciminale V., Casareto L.,
RA   Mulloy J.C., Jacobson S., Franchini G.;
RT   "Free major histocompatibility complex class I heavy chain is
RT   preferentially targeted for degradation by human T-cell
RT   leukemia/lymphotropic virus type 1 p12(I) protein.";
RL   J. Virol. 75:6086-6094(2001).
RN   [38]
RP   INTERACTION WITH HUMAN HERPESVIRUS 8 MIR1 PROTEIN, AND UBIQUITINATION.
RX   PubMed=12006494; DOI=10.1093/emboj/21.10.2418;
RA   Hewitt E.W., Duncan L., Mufti D., Baker J., Stevenson P.G.,
RA   Lehner P.J.;
RT   "Ubiquitylation of MHC class I by the K3 viral protein signals
RT   internalization and TSG101-dependent degradation.";
RL   EMBO J. 21:2418-2429(2002).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 25-300 OF HLA-A/B2M
RP   HETERODIMER IN COMPLEX WITH TRAC AND TRBC1, AND DISULFIDE BONDS.
RX   PubMed=12796775; DOI=10.1038/ni942;
RA   Stewart-Jones G.B.E., McMichael A.J., Bell J.I., Stuart D.I.,
RA   Jones E.Y.;
RT   "A structural basis for immunodominant human T cell receptor
RT   recognition.";
RL   Nat. Immunol. 4:657-663(2003).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF A*02:01.
RX   MEDLINE=91245570; PubMed=2038058; DOI=10.1016/0022-2836(91)90567-P;
RA   Saper M.A., Bjorkman P.J., Wiley D.C.;
RT   "Refined structure of the human histocompatibility antigen HLA-A2 at
RT   2.6-A resolution.";
RL   J. Mol. Biol. 219:277-319(1991).
CC   -!- FUNCTION: Involved in the presentation of foreign antigens to the
CC       immune system.
CC   -!- SUBUNIT: Dimer of alpha chain and a beta chain (beta-2-
CC       microglobulin). Interacts with human herpesvirus 8 MIR1 protein.
CC       Interacts with HTLV-1 accessory protein p12I.
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- PTM: Polyubiquitinated in a post ER compartment through
CC       interaction with human herpesvirus 8 MIR1 protein. This targets
CC       the protein for rapid degradation via the ubiquitin system.
CC   -!- POLYMORPHISM: The following alleles of A-2 are known: A*02:01,
CC       A*02:02, A*02:03, A*02:04, A*02:05, A*02:06 (A2.4A), A*02:07,
CC       A*02:08, A*02:09, A*02:10, A*02:11 (A2.5), A*02:12, A*02:13
CC       (A*02SLU), A*02:16, A*02:17, A*02:18 (A2K), A*02:19, A*02:20,
CC       A*02:21, A*02:31, A*02:34 (A*AAT), A*02:35, A*02:36 and A*02:37.
CC       The sequence shown is that of A*02:01.
CC   -!- SIMILARITY: Belongs to the MHC class I family.
CC   -!- SIMILARITY: Contains 1 Ig-like C1-type (immunoglobulin-like)
CC       domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA41022.1; Type=Miscellaneous discrepancy; Note=The sequence differs from that shown extensively;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; K02883; AAA98727.1; -; Genomic_DNA.
DR   EMBL; M84379; AAA59606.1; -; mRNA.
DR   EMBL; X02457; CAA26297.1; -; mRNA.
DR   EMBL; M11887; AAA52656.1; -; mRNA.
DR   EMBL; M19670; AAA03683.2; -; Genomic_DNA.
DR   EMBL; AH003586; AAB02120.1; -; Genomic_DNA.
DR   EMBL; U03863; AAA03604.1; -; mRNA.
DR   EMBL; M86404; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; X57954; CAA41022.1; ALT_SEQ; mRNA.
DR   EMBL; U02935; AAA76608.2; -; Genomic_DNA.
DR   EMBL; AJ555412; CAD87771.1; -; Genomic_DNA.
DR   EMBL; U03862; AAA03603.1; -; mRNA.
DR   EMBL; M24042; AAA59653.1; -; mRNA.
DR   EMBL; Z23071; CAA80612.1; -; mRNA.
DR   EMBL; M84377; AAA59603.1; -; mRNA.
DR   EMBL; X60764; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; M84378; AAA59604.1; -; mRNA.
DR   EMBL; Z27120; CAA81644.1; -; mRNA.
DR   EMBL; Z46633; CAA86602.1; -; mRNA.
DR   EMBL; U18930; AAA87076.1; -; mRNA.
DR   EMBL; D83515; BAA11935.1; -; mRNA.
DR   EMBL; X96724; CAA65501.1; -; mRNA.
DR   EMBL; U56825; AAB17465.1; -; mRNA.
DR   EMBL; AH007560; AAD23437.1; -; Genomic_DNA.
DR   EMBL; AH007704; AAD30272.1; -; Genomic_DNA.
DR   EMBL; AH008013; AAD45690.1; -; Genomic_DNA.
DR   EMBL; AH008012; AAD45689.1; -; Genomic_DNA.
DR   EMBL; AH008007; AAD45324.1; -; Genomic_DNA.
DR   IPI; IPI00876963; -.
DR   PIR; B24512; HLHU10.
DR   PIR; I37470; I37470.
DR   PIR; I37542; I37542.
DR   PIR; I38418; I38418.
DR   PIR; I38442; I38442.
DR   PIR; I38443; I38443.
DR   PIR; I55948; HLHUA2.
DR   PIR; I61857; I61857.
DR   PIR; I61902; I61902.
DR   PIR; I84448; I84448.
DR   UniGene; Hs.181244; -.
DR   UniGene; Hs.713441; -.
DR   PDB; 1AKJ; X-ray; 2.65 A; A=25-300.
DR   PDB; 1AO7; X-ray; 2.60 A; A=25-299.
DR   PDB; 1AQD; X-ray; 2.45 A; C/F/I/L=127-141.
DR   PDB; 1B0G; X-ray; 2.50 A; A/D=25-299.
DR   PDB; 1B0R; X-ray; 2.90 A; A=25-299.
DR   PDB; 1BD2; X-ray; 2.50 A; A=25-299.
DR   PDB; 1DUY; X-ray; 2.15 A; A/D=25-299.
DR   PDB; 1DUZ; X-ray; 1.80 A; A/D=25-299.
DR   PDB; 1EEY; X-ray; 2.25 A; A/D=25-299.
DR   PDB; 1EEZ; X-ray; 2.30 A; A/D=25-299.
DR   PDB; 1HHG; X-ray; 2.60 A; A/D=25-299.
DR   PDB; 1HHH; X-ray; 3.00 A; A=25-299.
DR   PDB; 1HHI; X-ray; 2.50 A; A/D=25-299.
DR   PDB; 1HHJ; X-ray; 2.50 A; A/D=25-299.
DR   PDB; 1HHK; X-ray; 2.50 A; A/D=25-299.
DR   PDB; 1HLA; X-ray; 3.50 A; A=25-294.
DR   PDB; 1I1F; X-ray; 2.80 A; A/D=25-299.
DR   PDB; 1I1Y; X-ray; 2.20 A; A/D=25-299.
DR   PDB; 1I4F; X-ray; 1.40 A; A=25-299.
DR   PDB; 1I7R; X-ray; 2.20 A; A/D=25-299.
DR   PDB; 1I7T; X-ray; 2.80 A; A/D=25-299.
DR   PDB; 1I7U; X-ray; 1.80 A; A/D=25-299.
DR   PDB; 1IM3; X-ray; 2.20 A; A/E/I/M=25-299.
DR   PDB; 1JF1; X-ray; 1.85 A; A=25-299.
DR   PDB; 1JHT; X-ray; 2.15 A; A=25-299.
DR   PDB; 1LP9; X-ray; 2.00 A; A/H=25-299.
DR   PDB; 1OGA; X-ray; 1.40 A; A=25-300.
DR   PDB; 1P7Q; X-ray; 3.40 A; A=25-300.
DR   PDB; 1QEW; X-ray; 2.20 A; A=25-299.
DR   PDB; 1QR1; X-ray; 2.40 A; A/D=25-299.
DR   PDB; 1QRN; X-ray; 2.80 A; A=25-298.
DR   PDB; 1QSE; X-ray; 2.80 A; A=25-298.
DR   PDB; 1QSF; X-ray; 2.80 A; A=25-298.
DR   PDB; 1S8D; X-ray; 2.20 A; A=25-299.
DR   PDB; 1S9W; X-ray; 2.20 A; A=25-298.
DR   PDB; 1S9X; X-ray; 2.50 A; A=25-298.
DR   PDB; 1S9Y; X-ray; 2.30 A; A=25-298.
DR   PDB; 1T1W; X-ray; 2.20 A; A=25-299.
DR   PDB; 1T1X; X-ray; 2.20 A; A=25-299.
DR   PDB; 1T1Y; X-ray; 2.00 A; A=25-299.
DR   PDB; 1T1Z; X-ray; 1.90 A; A=25-299.
DR   PDB; 1T20; X-ray; 2.20 A; A=25-299.
DR   PDB; 1T21; X-ray; 2.19 A; A=25-299.
DR   PDB; 1T22; X-ray; 2.20 A; A=25-299.
DR   PDB; 1TVB; X-ray; 1.80 A; A/D=25-299.
DR   PDB; 1TVH; X-ray; 1.80 A; A/D=25-299.
DR   PDB; 1UR7; Model; -; A=25-299.
DR   PDB; 2AV1; X-ray; 1.95 A; A/D=25-299.
DR   PDB; 2AV7; X-ray; 2.05 A; A/D=25-299.
DR   PDB; 2BNQ; X-ray; 1.70 A; A=25-300.
DR   PDB; 2BNR; X-ray; 1.90 A; A=25-300.
DR   PDB; 2C7U; X-ray; 2.38 A; A/D=25-300.
DR   PDB; 2CLR; X-ray; 2.00 A; A/D=25-299.
DR   PDB; 2F53; X-ray; 2.10 A; A=25-299.
DR   PDB; 2F54; X-ray; 2.70 A; A/F=25-298.
DR   PDB; 2GIT; X-ray; 1.70 A; A/D=25-299.
DR   PDB; 2GJ6; X-ray; 2.56 A; A=25-299.
DR   PDB; 2GT9; X-ray; 1.75 A; A/D=25-299.
DR   PDB; 2GTW; X-ray; 1.55 A; A/D=25-299.
DR   PDB; 2GTZ; X-ray; 1.70 A; A/D=25-299.
DR   PDB; 2GUO; X-ray; 1.90 A; A/D=25-299.
DR   PDB; 2J8U; X-ray; 2.88 A; A/H=25-299.
DR   PDB; 2JCC; X-ray; 2.50 A; A/H=25-299.
DR   PDB; 2P5E; X-ray; 1.89 A; A=25-300.
DR   PDB; 2P5W; X-ray; 2.20 A; A=25-300.
DR   PDB; 2PYE; X-ray; 2.30 A; A=25-300.
DR   PDB; 2UWE; X-ray; 2.40 A; A/H=25-299.
DR   PDB; 2V2W; X-ray; 1.60 A; A/D=25-300.
DR   PDB; 2V2X; X-ray; 1.60 A; A/D=25-300.
DR   PDB; 2VLJ; X-ray; 2.40 A; A=25-300.
DR   PDB; 2VLK; X-ray; 2.50 A; A=25-300.
DR   PDB; 2VLL; X-ray; 1.60 A; A/D=25-300.
DR   PDB; 2VLR; X-ray; 2.30 A; A/F=25-300.
DR   PDB; 2X4N; X-ray; 2.34 A; A/D=25-299.
DR   PDB; 2X4O; X-ray; 2.30 A; A/D=25-299.
DR   PDB; 2X4P; X-ray; 2.30 A; A/D=25-299.
DR   PDB; 2X4Q; X-ray; 1.90 A; A/D=25-299.
DR   PDB; 2X4R; X-ray; 2.30 A; A/D=25-299.
DR   PDB; 2X4S; X-ray; 2.55 A; A/D=25-299.
DR   PDB; 2X4T; X-ray; 2.30 A; A/D=25-299.
DR   PDB; 2X4U; X-ray; 2.10 A; A/D=25-299.
DR   PDB; 2X70; X-ray; 2.00 A; A/D=25-299.
DR   PDB; 3BGM; X-ray; 1.60 A; A=25-298.
DR   PDB; 3BH8; X-ray; 1.65 A; A=25-298.
DR   PDB; 3BH9; X-ray; 1.70 A; A=25-299.
DR   PDB; 3BHB; X-ray; 2.20 A; A=25-298.
DR   PDB; 3D25; X-ray; 1.30 A; A=25-298.
DR   PDB; 3D39; X-ray; 2.81 A; A=25-299.
DR   PDB; 3D3V; X-ray; 2.80 A; A=25-299.
DR   PDB; 3FQN; X-ray; 1.65 A; A=25-299.
DR   PDB; 3FQR; X-ray; 1.70 A; A=25-299.
DR   PDB; 3FQT; X-ray; 1.80 A; A=25-299.
DR   PDB; 3FQU; X-ray; 1.80 A; A=25-299.
DR   PDB; 3FQW; X-ray; 1.93 A; A=25-299.
DR   PDB; 3FQX; X-ray; 1.70 A; A=25-299.
DR   PDB; 3FT2; X-ray; 1.80 A; A=25-299.
DR   PDB; 3FT3; X-ray; 1.95 A; A=25-299.
DR   PDB; 3FT4; X-ray; 1.90 A; A=25-299.
DR   PDB; 3GIV; X-ray; 2.00 A; A/D=25-299.
DR   PDB; 3GJF; X-ray; 1.90 A; A/D=25-300.
DR   PDB; 3GSN; X-ray; 2.80 A; H=25-298.
DR   PDB; 3GSO; X-ray; 1.60 A; A=25-298.
DR   PDB; 3GSQ; X-ray; 2.12 A; A=25-298.
DR   PDB; 3GSR; X-ray; 1.95 A; A=25-298.
DR   PDB; 3GSU; X-ray; 1.80 A; A=25-299.
DR   PDB; 3GSV; X-ray; 1.90 A; A=25-299.
DR   PDB; 3GSW; X-ray; 1.81 A; A=25-298.
DR   PDB; 3GSX; X-ray; 2.10 A; A=25-298.
DR   PDB; 3H7B; X-ray; 1.88 A; A/D=25-299.
DR   PDB; 3H9H; X-ray; 2.00 A; A/D=25-299.
DR   PDB; 3H9S; X-ray; 2.70 A; A=25-299.
DR   PDB; 3HAE; X-ray; 2.90 A; A/D/J/P=25-300.
DR   PDB; 3HG1; X-ray; 3.00 A; A=25-300.
DR   PDB; 3HLA; X-ray; 2.60 A; A=25-294.
DR   PDB; 3HPJ; X-ray; 2.00 A; A/D=25-299.
DR   PDB; 3I6G; X-ray; 2.20 A; A/D=25-299.
DR   PDB; 3I6K; X-ray; 2.80 A; A/E=25-299.
DR   PDB; 3IXA; X-ray; 2.10 A; A/D=25-299.
DR   PDB; 3KLA; X-ray; 1.65 A; A/D=25-299.
DR   PDB; 3MGO; X-ray; 2.30 A; A/D/G/J=25-299.
DR   PDB; 3MGT; X-ray; 2.20 A; A/D/G/J=25-299.
DR   PDB; 3MR9; X-ray; 1.93 A; A=25-300.
DR   PDB; 3MRB; X-ray; 1.40 A; A=25-300.
DR   PDB; 3MRC; X-ray; 1.80 A; A=25-300.
DR   PDB; 3MRD; X-ray; 1.70 A; A=25-300.
DR   PDB; 3MRE; X-ray; 1.10 A; A=25-300.
DR   PDB; 3MRF; X-ray; 2.30 A; A=25-300.
DR   PDB; 3MRG; X-ray; 1.30 A; A=25-300.
DR   PDB; 3MRH; X-ray; 2.40 A; A=25-300.
DR   PDB; 3MRI; X-ray; 2.10 A; A=25-300.
DR   PDB; 3MRJ; X-ray; 1.87 A; A=25-300.
DR   PDB; 3MRK; X-ray; 1.40 A; A=25-300.
DR   PDB; 3MRL; X-ray; 2.41 A; A=25-300.
DR   PDB; 3MRM; X-ray; 1.90 A; A=25-300.
DR   PDB; 3MRN; X-ray; 2.30 A; A=25-300.
DR   PDB; 3MRO; X-ray; 2.35 A; A=25-300.
DR   PDB; 3MRP; X-ray; 2.10 A; A=25-300.
DR   PDB; 3MRQ; X-ray; 2.20 A; A=25-300.
DR   PDB; 3MRR; X-ray; 1.60 A; A=25-300.
DR   PDB; 3MYJ; X-ray; 1.89 A; A/D=25-299.
DR   PDB; 3O3A; X-ray; 1.80 A; A/D=25-299.
DR   PDB; 3O3B; X-ray; 1.90 A; A/D=25-299.
DR   PDB; 3O3D; X-ray; 1.70 A; A/D=25-299.
DR   PDB; 3O3E; X-ray; 1.85 A; A/D=25-299.
DR   PDB; 3O4L; X-ray; 2.54 A; A=25-300.
DR   PDB; 3PWJ; X-ray; 1.70 A; A/D=25-299.
DR   PDB; 3PWL; X-ray; 1.65 A; A/D=25-299.
DR   PDB; 3PWN; X-ray; 1.60 A; A/D=25-299.
DR   PDB; 3PWP; X-ray; 2.69 A; A=25-299.
DR   PDB; 3QDG; X-ray; 2.69 A; A=25-299.
DR   PDB; 3QDJ; X-ray; 2.30 A; A=25-299.
DR   PDB; 3QDM; X-ray; 2.80 A; A=25-299.
DR   PDB; 3QEQ; X-ray; 2.59 A; A=25-299.
DR   PDB; 3QFD; X-ray; 1.68 A; A/D=25-299.
DR   PDB; 3QFJ; X-ray; 2.29 A; A=25-299.
DR   PDB; 3REW; X-ray; 1.90 A; A/D=25-299.
DR   PDB; 3TO2; X-ray; 2.60 A; A=25-299.
DR   PDB; 3UTQ; X-ray; 1.67 A; A=25-300.
DR   PDB; 3UTS; X-ray; 2.71 A; A/F=25-300.
DR   PDB; 3UTT; X-ray; 2.60 A; A/F=25-299.
DR   PDB; 4E5X; X-ray; 1.95 A; A/D=25-299.
DR   PDB; 4EMZ; X-ray; 2.90 A; D/E=338-365.
DR   PDB; 4EN2; X-ray; 2.58 A; D/E=338-365.
DR   PDB; 4GKN; X-ray; 2.75 A; A/D=25-300.
DR   PDB; 4GKS; X-ray; 2.35 A; A/D=25-300.
DR   PDBsum; 1AKJ; -.
DR   PDBsum; 1AO7; -.
DR   PDBsum; 1AQD; -.
DR   PDBsum; 1B0G; -.
DR   PDBsum; 1B0R; -.
DR   PDBsum; 1BD2; -.
DR   PDBsum; 1DUY; -.
DR   PDBsum; 1DUZ; -.
DR   PDBsum; 1EEY; -.
DR   PDBsum; 1EEZ; -.
DR   PDBsum; 1HHG; -.
DR   PDBsum; 1HHH; -.
DR   PDBsum; 1HHI; -.
DR   PDBsum; 1HHJ; -.
DR   PDBsum; 1HHK; -.
DR   PDBsum; 1HLA; -.
DR   PDBsum; 1I1F; -.
DR   PDBsum; 1I1Y; -.
DR   PDBsum; 1I4F; -.
DR   PDBsum; 1I7R; -.
DR   PDBsum; 1I7T; -.
DR   PDBsum; 1I7U; -.
DR   PDBsum; 1IM3; -.
DR   PDBsum; 1JF1; -.
DR   PDBsum; 1JHT; -.
DR   PDBsum; 1LP9; -.
DR   PDBsum; 1OGA; -.
DR   PDBsum; 1P7Q; -.
DR   PDBsum; 1QEW; -.
DR   PDBsum; 1QR1; -.
DR   PDBsum; 1QRN; -.
DR   PDBsum; 1QSE; -.
DR   PDBsum; 1QSF; -.
DR   PDBsum; 1S8D; -.
DR   PDBsum; 1S9W; -.
DR   PDBsum; 1S9X; -.
DR   PDBsum; 1S9Y; -.
DR   PDBsum; 1T1W; -.
DR   PDBsum; 1T1X; -.
DR   PDBsum; 1T1Y; -.
DR   PDBsum; 1T1Z; -.
DR   PDBsum; 1T20; -.
DR   PDBsum; 1T21; -.
DR   PDBsum; 1T22; -.
DR   PDBsum; 1TVB; -.
DR   PDBsum; 1TVH; -.
DR   PDBsum; 1UR7; -.
DR   PDBsum; 2AV1; -.
DR   PDBsum; 2AV7; -.
DR   PDBsum; 2BNQ; -.
DR   PDBsum; 2BNR; -.
DR   PDBsum; 2C7U; -.
DR   PDBsum; 2CLR; -.
DR   PDBsum; 2F53; -.
DR   PDBsum; 2F54; -.
DR   PDBsum; 2GIT; -.
DR   PDBsum; 2GJ6; -.
DR   PDBsum; 2GT9; -.
DR   PDBsum; 2GTW; -.
DR   PDBsum; 2GTZ; -.
DR   PDBsum; 2GUO; -.
DR   PDBsum; 2J8U; -.
DR   PDBsum; 2JCC; -.
DR   PDBsum; 2P5E; -.
DR   PDBsum; 2P5W; -.
DR   PDBsum; 2PYE; -.
DR   PDBsum; 2UWE; -.
DR   PDBsum; 2V2W; -.
DR   PDBsum; 2V2X; -.
DR   PDBsum; 2VLJ; -.
DR   PDBsum; 2VLK; -.
DR   PDBsum; 2VLL; -.
DR   PDBsum; 2VLR; -.
DR   PDBsum; 2X4N; -.
DR   PDBsum; 2X4O; -.
DR   PDBsum; 2X4P; -.
DR   PDBsum; 2X4Q; -.
DR   PDBsum; 2X4R; -.
DR   PDBsum; 2X4S; -.
DR   PDBsum; 2X4T; -.
DR   PDBsum; 2X4U; -.
DR   PDBsum; 2X70; -.
DR   PDBsum; 3BGM; -.
DR   PDBsum; 3BH8; -.
DR   PDBsum; 3BH9; -.
DR   PDBsum; 3BHB; -.
DR   PDBsum; 3D25; -.
DR   PDBsum; 3D39; -.
DR   PDBsum; 3D3V; -.
DR   PDBsum; 3FQN; -.
DR   PDBsum; 3FQR; -.
DR   PDBsum; 3FQT; -.
DR   PDBsum; 3FQU; -.
DR   PDBsum; 3FQW; -.
DR   PDBsum; 3FQX; -.
DR   PDBsum; 3FT2; -.
DR   PDBsum; 3FT3; -.
DR   PDBsum; 3FT4; -.
DR   PDBsum; 3GIV; -.
DR   PDBsum; 3GJF; -.
DR   PDBsum; 3GSN; -.
DR   PDBsum; 3GSO; -.
DR   PDBsum; 3GSQ; -.
DR   PDBsum; 3GSR; -.
DR   PDBsum; 3GSU; -.
DR   PDBsum; 3GSV; -.
DR   PDBsum; 3GSW; -.
DR   PDBsum; 3GSX; -.
DR   PDBsum; 3H7B; -.
DR   PDBsum; 3H9H; -.
DR   PDBsum; 3H9S; -.
DR   PDBsum; 3HAE; -.
DR   PDBsum; 3HG1; -.
DR   PDBsum; 3HLA; -.
DR   PDBsum; 3HPJ; -.
DR   PDBsum; 3I6G; -.
DR   PDBsum; 3I6K; -.
DR   PDBsum; 3IXA; -.
DR   PDBsum; 3KLA; -.
DR   PDBsum; 3MGO; -.
DR   PDBsum; 3MGT; -.
DR   PDBsum; 3MR9; -.
DR   PDBsum; 3MRB; -.
DR   PDBsum; 3MRC; -.
DR   PDBsum; 3MRD; -.
DR   PDBsum; 3MRE; -.
DR   PDBsum; 3MRF; -.
DR   PDBsum; 3MRG; -.
DR   PDBsum; 3MRH; -.
DR   PDBsum; 3MRI; -.
DR   PDBsum; 3MRJ; -.
DR   PDBsum; 3MRK; -.
DR   PDBsum; 3MRL; -.
DR   PDBsum; 3MRM; -.
DR   PDBsum; 3MRN; -.
DR   PDBsum; 3MRO; -.
DR   PDBsum; 3MRP; -.
DR   PDBsum; 3MRQ; -.
DR   PDBsum; 3MRR; -.
DR   PDBsum; 3MYJ; -.
DR   PDBsum; 3O3A; -.
DR   PDBsum; 3O3B; -.
DR   PDBsum; 3O3D; -.
DR   PDBsum; 3O3E; -.
DR   PDBsum; 3O4L; -.
DR   PDBsum; 3PWJ; -.
DR   PDBsum; 3PWL; -.
DR   PDBsum; 3PWN; -.
DR   PDBsum; 3PWP; -.
DR   PDBsum; 3QDG; -.
DR   PDBsum; 3QDJ; -.
DR   PDBsum; 3QDM; -.
DR   PDBsum; 3QEQ; -.
DR   PDBsum; 3QFD; -.
DR   PDBsum; 3QFJ; -.
DR   PDBsum; 3REW; -.
DR   PDBsum; 3TO2; -.
DR   PDBsum; 3UTQ; -.
DR   PDBsum; 3UTS; -.
DR   PDBsum; 3UTT; -.
DR   PDBsum; 4E5X; -.
DR   PDBsum; 4EMZ; -.
DR   PDBsum; 4EN2; -.
DR   PDBsum; 4GKN; -.
DR   PDBsum; 4GKS; -.
DR   ProteinModelPortal; P01892; -.
DR   SMR; P01892; 25-298.
DR   DIP; DIP-6085N; -.
DR   IntAct; P01892; 6.
DR   MINT; MINT-5000859; -.
DR   STRING; P01892; -.
DR   PhosphoSite; P01892; -.
DR   DMDM; 122138; -.
DR   PaxDb; P01892; -.
DR   PRIDE; P01892; -.
DR   Ensembl; ENST00000457879; ENSP00000403575; ENSG00000235657.
DR   Ensembl; ENST00000547271; ENSP00000447962; ENSG00000235657.
DR   GeneCards; GC06P029921; -.
DR   GeneCards; GC06Pk29899; -.
DR   HGNC; HGNC:4931; HLA-A.
DR   MIM; 142800; gene.
DR   neXtProt; NX_P01892; -.
DR   eggNOG; NOG42056; -.
DR   HOVERGEN; HBG016709; -.
DR   OrthoDB; EOG4F4SBG; -.
DR   Reactome; REACT_116125; Disease.
DR   Reactome; REACT_6900; Immune System.
DR   EvolutionaryTrace; P01892; -.
DR   CleanEx; HS_HLA-A; -.
DR   Genevestigator; P01892; -.
DR   GermOnline; ENSG00000204632; Homo sapiens.
DR   GO; GO:0031901; C:early endosome membrane; TAS:Reactome.
DR   GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0071556; C:integral to lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0042612; C:MHC class I protein complex; IEA:UniProtKB-KW.
DR   GO; GO:0030670; C:phagocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0002479; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent; TAS:Reactome.
DR   GO; GO:0002480; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent; TAS:Reactome.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0050690; P:regulation of defense response to virus by virus; TAS:Reactome.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   GO; GO:0060337; P:type I interferon-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0016032; P:viral reproduction; TAS:Reactome.
DR   GO; GO:0019048; P:virus-host interaction; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.40.10; Ig-like_fold; 1.
DR   Gene3D; 3.30.500.10; MHC_I-like_Ag-recog; 1.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR011161; MHC_I-like_Ag-recog.
DR   InterPro; IPR011162; MHC_I/II-like_Ag-recog.
DR   InterPro; IPR001039; MHC_I_a_a1/a2.
DR   InterPro; IPR010579; MHC_I_a_C.
DR   Pfam; PF07654; C1-set; 1.
DR   Pfam; PF00129; MHC_I; 1.
DR   Pfam; PF06623; MHC_I_C; 1.
DR   PRINTS; PR01638; MHCCLASSI.
DR   SMART; SM00407; IGc1; 1.
DR   SUPFAM; SSF54452; MHC_I/II-like_Ag-recog; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Host-virus interaction; Immunity;
KW   Membrane; MHC I; Phosphoprotein; Polymorphism; Reference proteome;
KW   Signal; Transmembrane; Transmembrane helix; Ubl conjugation.
FT   SIGNAL        1     24
FT   CHAIN        25    365       HLA class I histocompatibility antigen,
FT                                A-2 alpha chain.
FT                                /FTId=PRO_0000018814.
FT   TOPO_DOM     25    308       Extracellular (Potential).
FT   TRANSMEM    309    332       Helical; (Potential).
FT   TOPO_DOM    333    365       Cytoplasmic (Potential).
FT   DOMAIN      209    295       Ig-like C1-type.
FT   REGION       25    114       Alpha-1.
FT   REGION      115    206       Alpha-2.
FT   REGION      207    298       Alpha-3.
FT   REGION      299    308       Connecting peptide.
FT   MOD_RES     352    352       Phosphoserine.
FT   MOD_RES     356    356       Phosphoserine.
FT   CARBOHYD    110    110       N-linked (GlcNAc...).
FT   DISULFID    125    188
FT   DISULFID    227    283
FT   VARIANT      33     33       F -> Y (in allele A*02:05, allele
FT                                A*02:06, allele A*02:08, allele A*02:10
FT                                and allele A*02:21).
FT                                /FTId=VAR_004334.
FT   VARIANT      54     54       D -> N (in allele A*02:21).
FT                                /FTId=VAR_004335.
FT   VARIANT      65     65       A -> G (in allele A*02:31).
FT                                /FTId=VAR_016726.
FT   VARIANT      67     67       Q -> R (in allele A*02:02, allele A*02:05
FT                                and allele A*02:08).
FT                                /FTId=VAR_004336.
FT   VARIANT      90     90       K -> N (in allele A*02:08 and allele
FT                                A*02:20).
FT                                /FTId=VAR_004337.
FT   VARIANT      94     94       H -> Q (in allele A*02:34 and allele
FT                                A*02:35).
FT                                /FTId=VAR_016727.
FT   VARIANT      97     97       T -> I (in allele A*02:11).
FT                                /FTId=VAR_004338.
FT   VARIANT      98     98       H -> D (in allele A*02:11 and allele
FT                                A*02:35).
FT                                /FTId=VAR_016728.
FT   VARIANT     119    119       V -> L (in allele A*02:02, allele
FT                                A*02:05, allele A*02:08 and allele
FT                                A*02:17).
FT                                /FTId=VAR_004339.
FT   VARIANT     121    121       R -> M (in allele A*02:04 and allele
FT                                A*02:17).
FT                                /FTId=VAR_004340.
FT   VARIANT     123    123       Y -> C (in allele A*02:07 and allele
FT                                A*02:18).
FT                                /FTId=VAR_004341.
FT   VARIANT     123    123       Y -> F (in allele A*02:10 and allele
FT                                A*02:17).
FT                                /FTId=VAR_004342.
FT   VARIANT     131    131       W -> G (in allele A*02:10).
FT                                /FTId=VAR_004343.
FT   VARIANT     162    162       M -> K (in allele A*02:18).
FT                                /FTId=VAR_004344.
FT   VARIANT     173    173       A -> T (in allele A*02:03).
FT                                /FTId=VAR_004345.
FT   VARIANT     176    176       V -> E (in allele A*02:03 and allele
FT                                A*02:13).
FT                                /FTId=VAR_004346.
FT   VARIANT     180    180       L -> Q (in allele A*02:12, allele A*02:13
FT                                and allele A*02:37).
FT                                /FTId=VAR_004348.
FT   VARIANT     180    180       L -> W (in allele A*02:02, allele
FT                                A*02:03, allele A*02:05 and allele
FT                                A*02:08).
FT                                /FTId=VAR_004347.
FT   VARIANT     187    187       T -> E (in allele A*02:16; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_004349.
FT   VARIANT     190    190       E -> D (in allele A*02:36 and allele
FT                                A*02:37).
FT                                /FTId=VAR_016729.
FT   VARIANT     191    191       W -> G (in allele A*02:36 and allele
FT                                A*02:37).
FT                                /FTId=VAR_016730.
FT   VARIANT     260    260       A -> E (in allele A*02:09).
FT                                /FTId=VAR_004350.
FT   CONFLICT    115    115       G -> V (in Ref. 4; AAA52656).
FT   CONFLICT    140    140       Y -> V (in Ref. 4; AAA52656).
FT   CONFLICT    277    277       Q -> E (in Ref. 4; AAA52656).
FT   CONFLICT    318    318       F -> L (in Ref. 4; AAA52656).
FT   STRAND       27     36
FT   STRAND       41     43
FT   STRAND       45     52
FT   STRAND       55     61
FT   STRAND       64     66
FT   STRAND       70     73
FT   HELIX        74     78
FT   HELIX        81    108
FT   STRAND      113    115
FT   STRAND      118    127
FT   STRAND      131    142
FT   STRAND      145    150
FT   STRAND      157    159
FT   HELIX       162    173
FT   HELIX       176    184
FT   HELIX       187    198
FT   HELIX       200    203
FT   STRAND      210    235
FT   STRAND      238    243
FT   STRAND      246    248
FT   HELIX       249    251
FT   STRAND      252    254
FT   STRAND      261    263
FT   STRAND      265    274
FT   HELIX       278    280
FT   STRAND      281    286
FT   STRAND      290    292
FT   STRAND      294    297
FT   STRAND      348    350
SQ   SEQUENCE   365 AA;  40922 MW;  B54A97B24B337C08 CRC64;
     MAVMAPRTLV LLLSGALALT QTWAGSHSMR YFFTSVSRPG RGEPRFIAVG YVDDTQFVRF
     DSDAASQRME PRAPWIEQEG PEYWDGETRK VKAHSQTHRV DLGTLRGYYN QSEAGSHTVQ
     RMYGCDVGSD WRFLRGYHQY AYDGKDYIAL KEDLRSWTAA DMAAQTTKHK WEAAHVAEQL
     RAYLEGTCVE WLRRYLENGK ETLQRTDAPK THMTHHAVSD HEATLRCWAL SFYPAEITLT
     WQRDGEDQTQ DTELVETRPA GDGTFQKWAA VVVPSGQEQR YTCHVQHEGL PKPLTLRWEP
     SSQPTIPIVG IIAGLVLFGA VITGAVVAAV MWRRKSSDRK GGSYSQAASS DSAQGSDVSL
     TACKV
//
ID   4F2_HUMAN               Reviewed;         630 AA.
AC   P08195; Q13543;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-SEP-2009, sequence version 3.
DT   28-NOV-2012, entry version 151.
DE   RecName: Full=4F2 cell-surface antigen heavy chain;
DE            Short=4F2hc;
DE   AltName: Full=4F2 heavy chain antigen;
DE   AltName: Full=Lymphocyte activation antigen 4F2 large subunit;
DE   AltName: CD_antigen=CD98;
GN   Name=SLC3A2; Synonyms=MDU1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   MEDLINE=87317685; PubMed=3476959; DOI=10.1073/pnas.84.18.6526;
RA   Quackenbush E., Clabby M., Gottesdiener K.M., Barbosa J., Jones N.H.,
RA   Strominger J.L., Speck S., Leiden J.M.;
RT   "Molecular cloning of complementary DNAs encoding the heavy chain of
RT   the human 4F2 cell-surface antigen: a type II membrane glycoprotein
RT   involved in normal and neoplastic cell growth.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:6526-6530(1987).
RN   [2]
RP   ERRATUM, AND SEQUENCE REVISION.
RA   Quackenbush E., Clabby M., Gottesdiener K.M., Barbosa J., Jones N.H.,
RA   Strominger J.L., Speck S., Leiden J.M.;
RL   Proc. Natl. Acad. Sci. U.S.A. 84:8618-8618(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   MEDLINE=87250620; PubMed=3036867;
RA   Teixeira S., di Grandi S., Kuehn L.C.;
RT   "Primary structure of the human 4F2 antigen heavy chain predicts a
RT   transmembrane protein with a cytoplasmic NH2 terminus.";
RL   J. Biol. Chem. 262:9574-9580(1987).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), TISSUE SPECIFICITY, AND
RP   INDUCTION.
RC   TISSUE=Fibroblast;
RX   MEDLINE=88097456; PubMed=3480538; DOI=10.1073/pnas.84.24.9204;
RA   Lumadue J.A., Glick A.B., Ruddle F.H.;
RT   "Cloning, sequence analysis, and expression of the large subunit of
RT   the human lymphocyte activation antigen 4F2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:9204-9208(1987).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORM 2),
RP   TISSUE SPECIFICITY, AND INDUCTION.
RX   MEDLINE=89127222; PubMed=3265470;
RA   Gottesdiener K.M., Karpinski B.A., Lindsten T., Strominger J.L.,
RA   Jones N.H., Thompson C.B., Leiden J.M.;
RT   "Isolation and structural characterization of the human 4F2 heavy-
RT   chain gene, an inducible gene involved in T-lymphocyte activation.";
RL   Mol. Cell. Biol. 8:3809-3819(1988).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, SUBUNIT, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Placenta;
RX   PubMed=11557028; DOI=10.1016/S0005-2736(01)00384-4;
RA   Yanagida O., Kanai Y., Chairoungdua A., Kim D.K., Segawa H., Nii T.,
RA   Cha S.H., Matsuo H., Fukushima J., Fukasawa Y., Tani Y., Taketani Y.,
RA   Uchino H., Kim J.Y., Inatomi J., Okayasu I., Miyamoto K., Takeda E.,
RA   Goya T., Endou H.;
RT   "Human L-type amino acid transporter 1 (LAT1): characterization of
RT   function and expression in tumor cell lines.";
RL   Biochim. Biophys. Acta 1514:291-302(2001).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND ALTERNATIVE
RP   SPLICING (ISOFORM 4).
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Lung, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PROTEIN SEQUENCE OF 1-17; 146-171; 227-245; 304-313; 440-451; 511-525
RP   AND 593-630, ACETYLATION AT MET-1, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RA   Bienvenut W.V., Lao L., Ryan K.L.;
RL   Submitted (OCT-2009) to UniProtKB.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 83-209 (ISOFORM 4).
RC   TISSUE=Lung carcinoma;
RA   Strausberg R.L.;
RL   Submitted (SEP-2000) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   PROTEIN SEQUENCE OF 112-122; 148-160; 227-245; 248-255; 288-298;
RP   304-313; 440-451; 511-524 AND 593-625, AND MASS SPECTROMETRY.
RC   TISSUE=B-cell lymphoma;
RA   Bienvenut W.V.;
RL   Submitted (MAR-2005) to UniProtKB.
RN   [12]
RP   FUNCTION, SUBUNIT, INHIBITION, AND MUTAGENESIS OF CYS-210 AND CYS-431.
RX   MEDLINE=99047611; PubMed=9829974; DOI=10.1074/jbc.273.49.32437;
RA   Torrents D., Estevez R., Pineda M., Fernandez E., Lloberas J.,
RA   Shi Y.-B., Zorzano A., Palacin M.;
RT   "Identification and characterization of a membrane protein (y+L amino
RT   acid transporter-1) that associates with 4F2hc to encode the amino
RT   acid transport activity y+L. A candidate gene for lysinuric protein
RT   intolerance.";
RL   J. Biol. Chem. 273:32437-32445(1998).
RN   [13]
RP   FUNCTION, AND SUBUNIT.
RX   MEDLINE=98421678; PubMed=9751058; DOI=10.1038/26246;
RA   Mastroberardino L., Spindler B., Pfeiffer R., Skelly P.J., Loffing J.,
RA   Shoemaker C.B., Verrey F.;
RT   "Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a
RT   permease family.";
RL   Nature 395:288-291(1998).
RN   [14]
RP   FUNCTION, AND SUBUNIT.
RX   MEDLINE=99094891; PubMed=9878049; DOI=10.1093/emboj/18.1.49;
RA   Pfeiffer R., Rossier G., Spindler B., Meier C., Kuehn L.C., Verrey F.;
RT   "Amino acid transport of y+L-type by heterodimers of 4F2hc/CD98 and
RT   members of the glycoprotein-associated amino acid transporter
RT   family.";
RL   EMBO J. 18:49-57(1999).
RN   [15]
RP   FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=10903140;
RA   Broeer A., Wagner C.A., Lang F., Broeer S.;
RT   "The heterodimeric amino acid transporter 4F2hc/y+LAT2 mediates
RT   arginine efflux in exchange with glutamine.";
RL   Biochem. J. 349:787-795(2000).
RN   [16]
RP   FUNCTION, SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=11311135;
RA   Broeer A., Friedrich B., Wagner C.A., Fillon S., Ganapathy V.,
RA   Lang F., Broeer S.;
RT   "Association of 4F2hc with light chains LAT1, LAT2 or y+LAT2 requires
RT   different domains.";
RL   Biochem. J. 355:725-731(2001).
RN   [17]
RP   FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=11389679; DOI=10.1042/0264-6021:3560719;
RA   Ritchie J.W.A., Taylor P.M.;
RT   "Role of the System L permease LAT1 in amino acid and iodothyronine
RT   transport in placenta.";
RL   Biochem. J. 356:719-725(2001).
RN   [18]
RP   SUBUNIT, INTERACTION WITH BETA-1 INTEGRINS, AND MUTAGENESIS OF CYS-210
RP   AND CYS-431.
RX   PubMed=11696247; DOI=10.1186/1472-2091-2-10;
RA   Kolesnikova T.V., Mannion B.A., Berditchevski F., Hemler M.E.;
RT   "Beta1 integrins show specific association with CD98 protein in low
RT   density membranes.";
RL   BMC Biochem. 2:10-10(2001).
RN   [19]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=11564694; DOI=10.1210/en.142.10.4339;
RA   Friesema E.C.H., Docter R., Moerings E.P.C.M., Verrey F.,
RA   Krenning E.P., Hennemann G., Visser T.J.;
RT   "Thyroid hormone transport by the heterodimeric human system L amino
RT   acid transporter.";
RL   Endocrinology 142:4339-4348(2001).
RN   [20]
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=11742812;
RA   Okamoto Y., Sakata M., Ogura K., Yamamoto T., Yamaguchi M., Tasaka K.,
RA   Kurachi H., Tsurudome M., Murata Y.;
RT   "Expression and regulation of 4F2hc and hLAT1 in human trophoblasts.";
RL   Am. J. Physiol. 282:C196-C204(2002).
RN   [21]
RP   INTERACTION WITH FAM57A/CT120.
RX   MEDLINE=22230983; PubMed=12270127; DOI=10.1016/S0006-291X(02)02227-1;
RA   He X.H., Di Y., Li J., Xie Y., Tang Y., Zhang F., Wei L., Zhang Y.,
RA   Qin W.X., Huo K., Li Y., Wan D.F., Gu J.R.;
RT   "Molecular cloning and characterization of CT120, a novel membrane-
RT   associated gene involved in amino acid transport and glutathione
RT   metabolism.";
RL   Biochem. Biophys. Res. Commun. 297:528-536(2002).
RN   [22]
RP   FUNCTION.
RX   PubMed=12117417; DOI=10.1042/BJ20020841;
RA   Simmons-Willis T.A., Koh A.S., Clarkson T.W., Ballatori N.;
RT   "Transport of a neurotoxicant by molecular mimicry: the methylmercury-
RT   L-cysteine complex is a substrate for human L-type large neutral amino
RT   acid transporter (LAT) 1 and LAT2.";
RL   Biochem. J. 367:239-246(2002).
RN   [23]
RP   FUNCTION, SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=12225859; DOI=10.1016/S0005-2736(02)00516-3;
RA   Kim D.K., Kanai Y., Choi H.W., Tangtrongsup S., Chairoungdua A.,
RA   Babu E., Tachampa K., Anzai N., Iribe Y., Endou H.;
RT   "Characterization of the system L amino acid transporter in T24 human
RT   bladder carcinoma cells.";
RL   Biochim. Biophys. Acta 1565:112-121(2002).
RN   [24]
RP   MASS SPECTROMETRY.
RC   TISSUE=Mammary cancer;
RX   MEDLINE=21829512; PubMed=11840567;
RX   DOI=10.1002/1615-9861(200202)2:2<212::AID-PROT212>3.0.CO;2-H;
RA   Harris R.A., Yang A., Stein R.C., Lucy K., Brusten L., Herath A.,
RA   Parekh R., Waterfield M.D., O'Hare M.J., Neville M.A., Page M.J.,
RA   Zvelebil M.J.;
RT   "Cluster analysis of an extensive human breast cancer cell line
RT   protein expression map database.";
RL   Proteomics 2:212-223(2002).
RN   [25]
RP   FUNCTION, SUBUNIT, AND TISSUE SPECIFICITY.
RX   PubMed=14603368; DOI=10.1113/eph8802647;
RA   Arancibia-Garavilla Y., Toledo F., Casanello P., Sobrevia L.;
RT   "Nitric oxide synthesis requires activity of the cationic and neutral
RT   amino acid transport system y+L in human umbilical vein endothelium.";
RL   Exp. Physiol. 88:699-710(2003).
RN   [26]
RP   FUNCTION, SUBUNIT, INTERACTION WITH ICAM1, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=12716892; DOI=10.1074/jbc.M302777200;
RA   Liu X., Charrier L., Gewirtz A., Sitaraman S., Merlin D.;
RT   "CD98 and intracellular adhesion molecule I regulate the activity of
RT   amino acid transporter LAT-2 in polarized intestinal epithelia.";
RL   J. Biol. Chem. 278:23672-23677(2003).
RN   [27]
RP   GLYCOSYLATION AT ASN-365; ASN-381 AND ASN-424.
RX   MEDLINE=22660472; PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [28]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=15980244; DOI=10.1167/iovs.04-1175;
RA   Tomi M., Mori M., Tachikawa M., Katayama K., Terasaki T., Hosoya K.;
RT   "L-type amino acid transporter 1-mediated L-leucine transport at the
RT   inner blood-retinal barrier.";
RL   Invest. Ophthalmol. Vis. Sci. 46:2522-2530(2005).
RN   [29]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=15769744; DOI=10.1074/jbc.M413164200;
RA   Li S., Whorton A.R.;
RT   "Identification of stereoselective transporters for S-nitroso-L-
RT   cysteine: role of LAT1 and LAT2 in biological activity of S-
RT   nitrosothiols.";
RL   J. Biol. Chem. 280:20102-20110(2005).
RN   [30]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-381 AND ASN-424, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-103 AND THR-106, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [32]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=16496379; DOI=10.1002/ijc.21866;
RA   Nawashiro H., Otani N., Shinomiya N., Fukui S., Ooigawa H., Shima K.,
RA   Matsuo H., Kanai Y., Endou H.;
RT   "L-type amino acid transporter 1 as a potential molecular target in
RT   human astrocytic tumors.";
RL   Int. J. Cancer 119:484-492(2006).
RN   [33]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS], AND MASS SPECTROMETRY.
RC   TISSUE=Melanoma;
RX   PubMed=17081065; DOI=10.1021/pr060363j;
RA   Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H.,
RA   Mangini N.J., Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R.,
RA   Yamagishi S., Shabanowitz J., Hearing V.J., Wu C., Appella E.,
RA   Hunt D.F.;
RT   "Proteomic and bioinformatic characterization of the biogenesis and
RT   function of melanosomes.";
RL   J. Proteome Res. 5:3135-3144(2006).
RN   [34]
RP   UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-147, AND MASS
RP   SPECTROMETRY.
RX   PubMed=18781797; DOI=10.1021/pr800468j;
RA   Meierhofer D., Wang X., Huang L., Kaiser P.;
RT   "Quantitative analysis of global ubiquitination in HeLa cells by mass
RT   spectrometry.";
RL   J. Proteome Res. 7:4566-4576(2008).
RN   [35]
RP   PHOSPHORYLATION AT SER-406; SER-408; SER-410; SER-527 AND SER-531.
RX   PubMed=19065266; DOI=10.1371/journal.pone.0003895;
RA   Nguyen H.T.T., Dalmasso G., Yan Y., Obertone T.S., Sitaraman S.V.,
RA   Merlin D.;
RT   "Ecto-phosphorylation of CD98 regulates cell-cell interactions.";
RL   PLoS ONE 3:E3895-E3895(2008).
RN   [36]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-365; ASN-381 AND ASN-506,
RP   AND MASS SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [37]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-365; ASN-381; ASN-424 AND
RP   ASN-506, AND MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-
RT   linked cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-165, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [39]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 212-630, SUBUNIT, MUTAGENESIS
RP   OF CYS-210, SUBCELLULAR LOCATION, AND DISULFIDE BOND.
RX   PubMed=17724034; DOI=10.1074/jbc.M704524200;
RA   Fort J., de la Ballina L.R., Burghardt H.E., Ferrer-Costa C.,
RA   Turnay J., Ferrer-Orta C., Uson I., Zorzano A., Fernandez-Recio J.,
RA   Orozco M., Lizarbe M.A., Fita I., Palacin M.;
RT   "The structure of human 4F2hc ectodomain provides a model for
RT   homodimerization and electrostatic interaction with plasma membrane.";
RL   J. Biol. Chem. 282:31444-31452(2007).
CC   -!- FUNCTION: Required for the function of light chain amino-acid
CC       transporters. Involved in sodium-independent, high-affinity
CC       transport of large neutral amino acids such as phenylalanine,
CC       tyrosine, leucine, arginine and tryptophan. Involved in guiding
CC       and targeting of LAT1 and LAT2 to the plasma membrane. When
CC       associated with SLC7A6 or SLC7A7 acts as an arginine/glutamine
CC       exchanger, following an antiport mechanism for amino acid
CC       transport, influencing arginine release in exchange for
CC       extracellular amino acids. Plays a role in nitric oxide synthesis
CC       in human umbilical vein endothelial cells (HUVECs) via transport
CC       of L-arginine. Required for normal and neoplastic cell growth.
CC       When associated with SLC7A5/LAT1, is also involved in the
CC       transport of L-DOPA across the blood-brain barrier, and that of
CC       thyroid hormones triiodothyronine (T3) and thyroxine (T4) across
CC       the cell membrane in tissues such as placenta. Involved in the
CC       uptake of methylmercury (MeHg) when administered as the L-cysteine
CC       or D,L-homocysteine complexes, and hence plays a role in metal ion
CC       homeostasis and toxicity. When associated with SLC7A5 or SLC7A8,
CC       involved in the cellular activity of small molecular weight
CC       nitrosothiols, via the stereoselective transport of L-
CC       nitrosocysteine (L-CNSO) across the transmembrane. Together with
CC       ICAM1, regulates the transport activity LAT2 in polarized
CC       intestinal cells, by generating and delivering intracellular
CC       signals. When associated with SLC7A5, plays an important role in
CC       transporting L-leucine from the circulating blood to the retina
CC       across the inner blood-retinal barrier.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=295 uM for glutamine (in the presence of NaCl);
CC         KM=236 uM for leucine (in the presence of NaCl);
CC         KM=120 uM for arginine (in the presence of NaCl);
CC         KM=138 uM for arginine (in the absence of NaCl);
CC   -!- SUBUNIT: Disulfide-linked heterodimer of a glycosylated heavy
CC       chain and a non-glycosylated light chain (SLC7A5, SLC7A6, SLCA7A7,
CC       SLC7A8, SLC7A10 or SLCA7A11). Colocalizes with cadherins (By
CC       similarity). Interacts with FAM57A/CT120 and ICAM1. Constitutively
CC       and specifically associates with beta-1 integrins (alpha-2/beta-1,
CC       alpha-3/beta-1, alpha-5/beta-1 and alpha-6/beta-1), but minimally
CC       with alpha-4/beta-1.
CC   -!- SUBCELLULAR LOCATION: Apical cell membrane; Single-pass type II
CC       membrane protein. Melanosome. Note=Identified by mass spectrometry
CC       in melanosome fractions from stage I to stage IV. Localized to the
CC       plasma membrane when associated with SLC7A5 or SLC7A8. Localized
CC       to the placental apical membrane. Located selectively at cell-cell
CC       adhesion sites (By similarity). Colocalized with SLC7A8/LAT2 at
CC       the basolateral membrane of kidney proximal tubules and small
CC       intestine epithelia. Expressed in both luminal and abluminal
CC       membranes of brain capillary endothelial cells (By similarity).
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=P08195-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P08195-2; Sequence=VSP_037907;
CC       Name=3;
CC         IsoId=P08195-3; Sequence=VSP_037908;
CC       Name=4;
CC         IsoId=P08195-4; Sequence=VSP_037909;
CC   -!- TISSUE SPECIFICITY: Expressed ubiquitously in all tissues tested
CC       with highest levels detected in kidney, placenta and testis and
CC       weakest level in thymus. During gestation, expression in the
CC       placenta was significantly stronger at full-term than at the mid-
CC       trimester stage. Expressed in HUVECS and at low levels in resting
CC       peripheral blood T-lymphocytes and quiescent fibroblasts. Also
CC       expressed in fetal liver and in the astrocytic process of primary
CC       astrocytic gliomas. Expressed in retinal endothelial cells and in
CC       the intestinal epithelial cell line Caco-2 BBe.
CC   -!- INDUCTION: Expression is induced in resting peripheral blood T-
CC       lymphocytes following PHA stimulation. Expression increases at the
CC       time of maximal DNA synthesis, in fibroblasts stimulated to
CC       divide. Expression and the uptake of leucine is stimulated in
CC       mononuclear, cytotrophoblast-like choriocarcinoma cells by
CC       combined treatment with PMA and calcium ionophore.
CC   -!- PTM: Phosphorylation on Ser-406; Ser-408 or Ser-410 and on Ser-527
CC       or Ser-531 by ecto-protein kinases favors heterotypic cell-cell
CC       interactions.
CC   -!- MASS SPECTROMETRY: Mass=57944.93; Method=MALDI; Range=1-529;
CC       Source=PubMed:11840567;
CC   -!- MISCELLANEOUS: Arginine uptake is inhibited by increasing
CC       concentrations of leucine in the presence of Na(+).
CC   -!- SIMILARITY: Belongs to the SLC3A transporter family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J02939; AAA52497.1; -; mRNA.
DR   EMBL; J02769; AAA51540.1; -; mRNA.
DR   EMBL; J03569; AAA35536.1; -; mRNA.
DR   EMBL; M21904; AAA35489.1; -; Genomic_DNA.
DR   EMBL; M21898; AAA35489.1; JOINED; Genomic_DNA.
DR   EMBL; M21899; AAA35489.1; JOINED; Genomic_DNA.
DR   EMBL; M21900; AAA35489.1; JOINED; Genomic_DNA.
DR   EMBL; M21901; AAA35489.1; JOINED; Genomic_DNA.
DR   EMBL; M21902; AAA35489.1; JOINED; Genomic_DNA.
DR   EMBL; M21903; AAA35489.1; JOINED; Genomic_DNA.
DR   EMBL; AB018010; BAA84649.1; -; mRNA.
DR   EMBL; AP001160; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC001061; AAH01061.2; -; mRNA.
DR   EMBL; BC003000; AAH03000.2; -; mRNA.
DR   EMBL; BE794697; -; NOT_ANNOTATED_CDS; mRNA.
DR   IPI; IPI00027493; -.
DR   IPI; IPI00554481; -.
DR   IPI; IPI00554722; -.
DR   IPI; IPI00604710; -.
DR   PIR; A28455; SAHU4F.
DR   RefSeq; NP_001012680.1; NM_001012662.2.
DR   RefSeq; NP_001012682.1; NM_001012664.2.
DR   RefSeq; NP_001013269.1; NM_001013251.2.
DR   RefSeq; NP_002385.3; NM_002394.5.
DR   UniGene; Hs.502769; -.
DR   PDB; 2DH2; X-ray; 2.10 A; A=212-630.
DR   PDB; 2DH3; X-ray; 2.80 A; A/B=212-630.
DR   PDBsum; 2DH2; -.
DR   PDBsum; 2DH3; -.
DR   ProteinModelPortal; P08195; -.
DR   SMR; P08195; 212-630.
DR   IntAct; P08195; 8.
DR   STRING; P08195; -.
DR   CAZy; GH13; Glycoside Hydrolase Family 13.
DR   TCDB; 8.A.9.2.2; rBAT transport accessory protein (rBAT) family.
DR   PhosphoSite; P08195; -.
DR   DMDM; 257051063; -.
DR   PaxDb; P08195; -.
DR   PRIDE; P08195; -.
DR   DNASU; 6520; -.
DR   Ensembl; ENST00000338663; ENSP00000340815; ENSG00000168003.
DR   Ensembl; ENST00000377889; ENSP00000367121; ENSG00000168003.
DR   Ensembl; ENST00000377890; ENSP00000367122; ENSG00000168003.
DR   Ensembl; ENST00000377892; ENSP00000367124; ENSG00000168003.
DR   GeneID; 6520; -.
DR   KEGG; hsa:6520; -.
DR   UCSC; uc001nwc.3; human.
DR   UCSC; uc001nwd.3; human.
DR   UCSC; uc001nwf.3; human.
DR   CTD; 6520; -.
DR   GeneCards; GC11P062623; -.
DR   HGNC; HGNC:11026; SLC3A2.
DR   MIM; 158070; gene.
DR   neXtProt; NX_P08195; -.
DR   PharmGKB; PA35894; -.
DR   eggNOG; COG0366; -.
DR   HOGENOM; HOG000233529; -.
DR   HOVERGEN; HBG000023; -.
DR   InParanoid; P08195; -.
DR   KO; K06519; -.
DR   OMA; NMTVKGQ; -.
DR   OrthoDB; EOG4S7JPP; -.
DR   BioCyc; MetaCyc:ENSG00000168003-MONOMER; -.
DR   Pathway_Interaction_DB; nfat_tfpathway; Calcineurin-regulated NFAT-dependent transcription in lymphocytes.
DR   Reactome; REACT_15518; Transmembrane transport of small molecules.
DR   Reactome; REACT_19419; Amino acid and oligopeptide SLC transporters.
DR   Reactome; REACT_604; Hemostasis.
DR   EvolutionaryTrace; P08195; -.
DR   GenomeRNAi; 6520; -.
DR   NextBio; 25353; -.
DR   ArrayExpress; P08195; -.
DR   Bgee; P08195; -.
DR   CleanEx; HS_SLC3A2; -.
DR   Genevestigator; P08195; -.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral to membrane; NAS:UniProtKB.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005432; F:calcium:sodium antiporter activity; TAS:UniProtKB.
DR   GO; GO:0003824; F:catalytic activity; IEA:InterPro.
DR   GO; GO:0043169; F:cation binding; IEA:InterPro.
DR   GO; GO:0015175; F:neutral amino acid transmembrane transporter activity; ISS:UniProtKB.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0005975; P:carbohydrate metabolic process; IEA:InterPro.
DR   GO; GO:0016049; P:cell growth; NAS:UniProtKB.
DR   GO; GO:0060356; P:leucine import; ISS:UniProtKB.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0015827; P:tryptophan transport; ISS:UniProtKB.
DR   Gene3D; 2.60.40.1180; Glyco_hydro_13_b; 1.
DR   Gene3D; 3.20.20.80; Glyco_hydro_cat; 1.
DR   InterPro; IPR015902; Glyco_hydro_13.
DR   InterPro; IPR013780; Glyco_hydro_13_b.
DR   InterPro; IPR006047; Glyco_hydro_13_cat_dom.
DR   InterPro; IPR013781; Glyco_hydro_catalytic_dom.
DR   InterPro; IPR017853; Glycoside_hydrolase_SF.
DR   PANTHER; PTHR10357; PTHR10357; 1.
DR   Pfam; PF00128; Alpha-amylase; 1.
DR   SUPFAM; SSF51445; Glyco_hydro_cat; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Amino-acid transport;
KW   Cell membrane; Complete proteome; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Isopeptide bond; Membrane;
KW   Phosphoprotein; Reference proteome; Signal-anchor; Transmembrane;
KW   Transmembrane helix; Transport; Ubl conjugation.
FT   CHAIN         1    630       4F2 cell-surface antigen heavy chain.
FT                                /FTId=PRO_0000064383.
FT   TOPO_DOM    102    184       Cytoplasmic (Potential).
FT   TRANSMEM    185    205       Helical; Signal-anchor for type II
FT                                membrane protein; (Potential).
FT   TOPO_DOM    206    630       Extracellular (Potential).
FT   MOD_RES       1      1       N-acetylmethionine.
FT   MOD_RES     103    103       Phosphoserine.
FT   MOD_RES     106    106       Phosphothreonine.
FT   MOD_RES     165    165       Phosphoserine.
FT   MOD_RES     406    406       Phosphoserine (Probable).
FT   MOD_RES     408    408       Phosphoserine (Probable).
FT   MOD_RES     410    410       Phosphoserine (Probable).
FT   MOD_RES     527    527       Phosphoserine (Probable).
FT   MOD_RES     531    531       Phosphoserine (Probable).
FT   CARBOHYD    365    365       N-linked (GlcNAc...).
FT   CARBOHYD    381    381       N-linked (GlcNAc...).
FT   CARBOHYD    424    424       N-linked (GlcNAc...).
FT   CARBOHYD    506    506       N-linked (GlcNAc...).
FT   DISULFID    210    210       Interchain (with light chain).
FT   CROSSLNK    147    147       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   VAR_SEQ       1    101       Missing (in isoform 2).
FT                                /FTId=VSP_037907.
FT   VAR_SEQ      38     99       Missing (in isoform 3).
FT                                /FTId=VSP_037908.
FT   VAR_SEQ      98     98       V -> VTETGFHHVSQADIEFLTSIDPTASASGSAGI (in
FT                                isoform 4).
FT                                /FTId=VSP_037909.
FT   MUTAGEN     210    210       C->S: Abolishes dimerization, leucine
FT                                uptake and interaction with beta-1
FT                                integrins.
FT   MUTAGEN     431    431       C->S: No effect on dimerization, leucine
FT                                uptake or interaction with beta-1
FT                                integrins.
FT   CONFLICT    137    137       G -> E (in Ref. 4; AAA35536).
FT   CONFLICT    158    158       A -> P (in Ref. 3; AAA51540).
FT   CONFLICT    223    223       A -> P (in Ref. 4; AAA35536).
FT   CONFLICT    315    315       E -> D (in Ref. 4; AAA35536).
FT   CONFLICT    320    320       S -> F (in Ref. 5; AAA35489).
FT   CONFLICT    372    372       E -> G (in Ref. 4; AAA35536).
FT   CONFLICT    412    413       GE -> PQ (in Ref. 4; AAA35536).
FT   CONFLICT    465    465       V -> L (in Ref. 4; AAA35536).
FT   CONFLICT    481    481       G -> P (in Ref. 4; AAA35536).
FT   CONFLICT    549    549       G -> E (in Ref. 5; AAA35489).
FT   CONFLICT    609    609       L -> P (in Ref. 4; AAA35536).
FT   CONFLICT    612    612       E -> G (in Ref. 4; AAA35536).
FT   HELIX       218    220
FT   STRAND      224    227
FT   HELIX       230    234
FT   HELIX       241    245
FT   HELIX       248    253
FT   STRAND      257    261
FT   STRAND      265    267
FT   STRAND      275    280
FT   HELIX       282    284
FT   HELIX       287    299
FT   STRAND      303    307
FT   TURN        310    313
FT   STRAND      314    316
FT   STRAND      319    321
FT   HELIX       323    340
FT   STRAND      344    347
FT   HELIX       350    352
FT   HELIX       356    370
FT   STRAND      375    379
FT   HELIX       385    391
FT   TURN        392    394
FT   STRAND      399    401
FT   TURN        404    407
FT   HELIX       412    426
FT   STRAND      437    439
FT   HELIX       441    443
FT   HELIX       447    449
FT   HELIX       450    457
FT   STRAND      460    467
FT   HELIX       470    472
FT   HELIX       476    478
FT   STRAND      479    481
FT   STRAND      484    486
FT   HELIX       493    495
FT   HELIX       500    502
FT   HELIX       505    507
FT   HELIX       509    513
FT   HELIX       519    532
FT   HELIX       534    538
FT   STRAND      540    545
FT   STRAND      550    556
FT   STRAND      562    568
FT   STRAND      570    572
FT   STRAND      581    583
FT   HELIX       585    587
FT   STRAND      591    603
FT   STRAND      607    610
FT   HELIX       611    613
FT   STRAND      621    626
SQ   SEQUENCE   630 AA;  67994 MW;  AE427F8204CC10B0 CRC64;
     MELQPPEASI AVVSIPRQLP GSHSEAGVQG LSAGDDSELG SHCVAQTGLE LLASGDPLPS
     ASQNAEMIET GSDCVTQAGL QLLASSDPPA LASKNAEVTG TMSQDTEVDM KEVELNELEP
     EKQPMNAASG AAMSLAGAEK NGLVKIKVAE DEAEAAAAAK FTGLSKEELL KVAGSPGWVR
     TRWALLLLFW LGWLGMLAGA VVIIVRAPRC RELPAQKWWH TGALYRIGDL QAFQGHGAGN
     LAGLKGRLDY LSSLKVKGLV LGPIHKNQKD DVAQTDLLQI DPNFGSKEDF DSLLQSAKKK
     SIRVILDLTP NYRGENSWFS TQVDTVATKV KDALEFWLQA GVDGFQVRDI ENLKDASSFL
     AEWQNITKGF SEDRLLIAGT NSSDLQQILS LLESNKDLLL TSSYLSDSGS TGEHTKSLVT
     QYLNATGNRW CSWSLSQARL LTSFLPAQLL RLYQLMLFTL PGTPVFSYGD EIGLDAAALP
     GQPMEAPVML WDESSFPDIP GAVSANMTVK GQSEDPGSLL SLFRRLSDQR SKERSLLHGD
     FHAFSAGPGL FSYIRHWDQN ERFLVVLNFG DVGLSAGLQA SDLPASASLP AKADLLLSTQ
     PGREEGSPLE LERLKLEPHE GLLLRFPYAA
//
ID   A1AG1_HUMAN             Reviewed;         201 AA.
AC   P02763; B7ZKQ5; Q5T539; Q5U067; Q8TC16;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1988, sequence version 1.
DT   28-NOV-2012, entry version 146.
DE   RecName: Full=Alpha-1-acid glycoprotein 1;
DE            Short=AGP 1;
DE   AltName: Full=Orosomucoid-1;
DE            Short=OMD 1;
DE   Flags: Precursor;
GN   Name=ORM1; Synonyms=AGP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=88029318; PubMed=2822385;
RA   Dente L., Pizza M.G., Metspalu A., Cortese R.;
RT   "Structure and expression of the genes coding for human alpha 1-acid
RT   glycoprotein.";
RL   EMBO J. 6:2289-2296(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=87031577; PubMed=3770479; DOI=10.1016/0378-1119(86)90051-X;
RA   Board P.G., Jones I.M., Bentley A.K.;
RT   "Molecular cloning and nucleotide sequence of human alpha 1 acid
RT   glycoprotein cDNA.";
RL   Gene 44:127-131(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=85242080; PubMed=2409529; DOI=10.1093/nar/13.11.3941;
RA   Dente L., Ciliberto G., Cortese R.;
RT   "Structure of the human alpha 1-acid glycoprotein gene: sequence
RT   homology with other human acute phase protein genes.";
RL   Nucleic Acids Res. 13:3941-3952(1985).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ARG-38.
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ARG-38.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ARG-38; CYS-167
RP   AND MET-174.
RC   TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PROTEIN SEQUENCE OF 19-129.
RX   MEDLINE=73197484; PubMed=4711474; DOI=10.1021/bi00738a026;
RA   Schmid K., Kaufmann H., Isemura S., Bauer F., Emura J., Motoyama T.,
RA   Ishiguro M., Nanno S.;
RT   "Structure of alpha 1-acid glycoprotein. The complete amino acid
RT   sequence, multiple amino acid substitutions, and homology with the
RT   immunoglobulins.";
RL   Biochemistry 12:2711-2724(1973).
RN   [10]
RP   PROTEIN SEQUENCE OF 129-201.
RX   MEDLINE=73006944; PubMed=4561179; DOI=10.1021/bi00770a022;
RA   Ikenaka T., Ishiguro M., Emura J., Kaufmann H., Isemura S., Bauer W.,
RA   Schmid K.;
RT   "Isolation and partial characterization of the cyanogen bromide
RT   fragments of alpha 1-acid glycoprotein and the elucidation of the
RT   amino acid sequence of the carboxyl-terminal cyanogen bromide
RT   fragment.";
RL   Biochemistry 11:3817-3829(1972).
RN   [11]
RP   DISULFIDE BONDS.
RX   MEDLINE=74290014; PubMed=4603214; DOI=10.1021/bi00710a006;
RA   Schmid K., Buergi W., Collins J.H., Nanno S.;
RT   "The disulfide bonds of alpha1-acid glycoprotein.";
RL   Biochemistry 13:2694-2697(1974).
RN   [12]
RP   GLYCOSYLATION AT ASN-33; ASN-56; ASN-72; ASN-93 AND ASN-103.
RX   MEDLINE=92231810; PubMed=1567356;
RA   Treuheit M.J., Costello C.E., Halsall H.B.;
RT   "Analysis of the five glycosylation sites of human alpha 1-acid
RT   glycoprotein.";
RL   Biochem. J. 283:105-112(1992).
RN   [13]
RP   GLYCOSYLATION AT ASN-33.
RX   MEDLINE=22660472; PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [14]
RP   GLYCOSYLATION AT ASN-33; ASN-72 AND ASN-93, AND MASS SPECTROMETRY.
RX   PubMed=15253437; DOI=10.1021/pr034112b;
RA   Hagglund P., Bunkenborg J., Elortza F., Jensen O.N., Roepstorff P.;
RT   "A new strategy for identification of N-glycosylated proteins and
RT   unambiguous assignment of their glycosylation sites using HILIC
RT   enrichment and partial deglycosylation.";
RL   J. Proteome Res. 3:556-566(2004).
RN   [15]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-33 AND ASN-93, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Bile;
RX   PubMed=15084671; DOI=10.1074/mcp.M400015-MCP200;
RA   Kristiansen T.Z., Bunkenborg J., Gronborg M., Molina H.,
RA   Thuluvath P.J., Argani P., Goggins M.G., Maitra A., Pandey A.;
RT   "A proteomic analysis of human bile.";
RL   Mol. Cell. Proteomics 3:715-728(2004).
RN   [16]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-33; ASN-56; ASN-72; ASN-93
RP   AND ASN-103, AND MASS SPECTROMETRY.
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [17]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-33; ASN-56; ASN-72; ASN-93
RP   AND ASN-103, AND MASS SPECTROMETRY.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [18]
RP   FUNCTION.
RX   PubMed=17008009; DOI=10.1016/j.bbagen.2006.08.015;
RA   Fitos I., Visy J., Zsila F., Mady G., Simonyi M.;
RT   "Selective binding of imatinib to the genetic variants of human
RT   alpha1-acid glycoprotein.";
RL   Biochim. Biophys. Acta 1760:1704-1712(2006).
RN   [19]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-93, AND MASS SPECTROMETRY.
RC   TISSUE=Saliva;
RX   PubMed=16740002; DOI=10.1021/pr050492k;
RA   Ramachandran P., Boontheung P., Xie Y., Sondej M., Wong D.T.,
RA   Loo J.A.;
RT   "Identification of N-linked glycoproteins in human saliva by
RT   glycoprotein capture and mass spectrometry.";
RL   J. Proteome Res. 5:1493-1503(2006).
RN   [20]
RP   FUNCTION.
RX   PubMed=17321687; DOI=10.1016/j.bbagen.2007.01.009;
RA   Zsila F., Iwao Y.;
RT   "The drug binding site of human alpha1-acid glycoprotein: insight from
RT   induced circular dichroism and electronic absorption spectra.";
RL   Biochim. Biophys. Acta 1770:797-809(2007).
RN   [21]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-93 AND ASN-103, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [22]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-33 AND ASN-72, STRUCTURE
RP   OF CARBOHYDRATES, AND MASS SPECTROMETRY.
RC   TISSUE=Cerebrospinal fluid;
RX   PubMed=19838169; DOI=10.1038/nmeth.1392;
RA   Nilsson J., Rueetschi U., Halim A., Hesse C., Carlsohn E.,
RA   Brinkmalm G., Larson G.;
RT   "Enrichment of glycopeptides for glycan structure and attachment site
RT   identification.";
RL   Nat. Methods 6:809-811(2009).
RN   [23]
RP   GLYCOSYLATION AT ASN-33, STRUCTURE OF CARBOHYDRATES, AND MASS
RP   SPECTROMETRY.
RX   PubMed=22171320; DOI=10.1074/mcp.M111.013649;
RA   Halim A., Nilsson J., Ruetschi U., Hesse C., Larson G.;
RT   "Human urinary glycoproteomics; attachment site specific analysis of
RT   N-and O-linked glycosylations by CID and ECD.";
RL   Mol. Cell. Proteomics 0:0-0(2011).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 20-201, DOMAIN, AND DISULFIDE
RP   BONDS.
RX   PubMed=18823996; DOI=10.1016/j.jmb.2008.09.020;
RA   Schonfeld D.L., Ravelli R.B., Mueller U., Skerra A.;
RT   "The 1.8-A crystal structure of alpha1-acid glycoprotein (Orosomucoid)
RT   solved by UV RIP reveals the broad drug-binding activity of this human
RT   plasma lipocalin.";
RL   J. Mol. Biol. 384:393-405(2008).
RN   [25]
RP   VARIANTS ARG-38 AND MET-174.
RX   MEDLINE=97203211; PubMed=9050929; DOI=10.1007/s004390050378;
RA   Yuasa I., Umetsu K., Vogt U., Nakamura H., Nanba E., Tamaki N.,
RA   Irizawa Y.;
RT   "Human orosomucoid polymorphism: molecular basis of the three common
RT   ORM1 alleles, ORM1*F1, ORM1*F2, and ORM1*S.";
RL   Hum. Genet. 99:393-398(1997).
CC   -!- FUNCTION: Functions as transport protein in the blood stream.
CC       Binds various ligands in the interior of its beta-barrel domain.
CC       Also binds synthetic drugs and influences their distribution and
CC       availability in the body. Appears to function in modulating the
CC       activity of the immune system during the acute-phase reaction.
CC   -!- INTERACTION:
CC       P05121:SERPINE1; NbExp=4; IntAct=EBI-976767, EBI-953978;
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: Expressed by the liver and secreted in plasma.
CC   -!- INDUCTION: Synthesis is controlled by glucocorticoids,
CC       interleukin-1 and interleukin-6, It increases 5- to 50-fold upon
CC       inflammation.
CC   -!- DOMAIN: Contains a beta-barrel that binds various ligands in its
CC       interior.
CC   -!- PTM: N-glycosylated. N-glycan heterogeneity at Asn-33: Hex5HexNAc4
CC       (minor), Hex6HexNAc5 (major) and dHex1Hex6HexNAc5 (minor).
CC   -!- POLYMORPHISM: Three common alleles of ORM1 are known. ORM1*F1 has
CC       Gln-38/Val-174; ORM1*F2 has Gln-38/Met-174 and ORM1*S has Arg-
CC       38/Val-174. The sequence shown is that of allele ORM1*F1.
CC   -!- SIMILARITY: Belongs to the calycin superfamily. Lipocalin family.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA29229.1; Type=Erroneous gene model prediction;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X02544; CAA26397.1; -; mRNA.
DR   EMBL; M13692; AAA35515.1; -; mRNA.
DR   EMBL; X05779; CAA29229.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; X05780; CAA29229.1; JOINED; Genomic_DNA.
DR   EMBL; X05781; CAA29229.1; JOINED; Genomic_DNA.
DR   EMBL; X05782; CAA29229.1; JOINED; Genomic_DNA.
DR   EMBL; X05783; CAA29229.1; JOINED; Genomic_DNA.
DR   EMBL; X05784; CAA29229.1; JOINED; Genomic_DNA.
DR   EMBL; X06676; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; X06680; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BT019790; AAV38593.1; -; mRNA.
DR   EMBL; AK312035; BAG34972.1; -; mRNA.
DR   EMBL; AL356796; CAI16859.1; -; Genomic_DNA.
DR   EMBL; CH471090; EAW87416.1; -; Genomic_DNA.
DR   EMBL; BC104818; AAI04819.1; -; mRNA.
DR   EMBL; BC104820; AAI04821.1; -; mRNA.
DR   EMBL; BC143313; AAI43314.1; -; mRNA.
DR   EMBL; BC143314; AAI43315.1; -; mRNA.
DR   EMBL; BC026238; AAH26238.1; -; mRNA.
DR   IPI; IPI00022429; -.
DR   PIR; A28346; OMHU1.
DR   RefSeq; NP_000598.2; NM_000607.2.
DR   UniGene; Hs.522356; -.
DR   PDB; 3KQ0; X-ray; 1.80 A; A=20-201.
DR   PDBsum; 3KQ0; -.
DR   ProteinModelPortal; P02763; -.
DR   SMR; P02763; 19-193.
DR   IntAct; P02763; 7.
DR   STRING; P02763; -.
DR   GlycoSuiteDB; P02763; -.
DR   PhosphoSite; P02763; -.
DR   DMDM; 112877; -.
DR   Siena-2DPAGE; P02763; -.
DR   SWISS-2DPAGE; P02763; -.
DR   PaxDb; P02763; -.
DR   PeptideAtlas; P02763; -.
DR   PRIDE; P02763; -.
DR   DNASU; 5004; -.
DR   Ensembl; ENST00000259396; ENSP00000259396; ENSG00000229314.
DR   GeneID; 5004; -.
DR   KEGG; hsa:5004; -.
DR   UCSC; uc004bik.4; human.
DR   CTD; 5004; -.
DR   GeneCards; GC09P117085; -.
DR   HGNC; HGNC:8498; ORM1.
DR   HPA; CAB006265; -.
DR   HPA; HPA046438; -.
DR   MIM; 138600; gene.
DR   neXtProt; NX_P02763; -.
DR   PharmGKB; PA260; -.
DR   eggNOG; NOG41523; -.
DR   HOGENOM; HOG000125170; -.
DR   HOVERGEN; HBG000035; -.
DR   InParanoid; P02763; -.
DR   OrthoDB; EOG4V9TS3; -.
DR   ChEMBL; CHEMBL4285; -.
DR   DrugBank; DB01418; Acenocoumarol.
DR   DrugBank; DB00802; Alfentanil.
DR   DrugBank; DB01429; Aprindine.
DR   DrugBank; DB00280; Disopyramide.
DR   DrugBank; DB01359; Penbutolol.
DR   DrugBank; DB00946; Phenprocoumon.
DR   DrugBank; DB00908; Quinidine.
DR   DrugBank; DB00706; Tamsulosin.
DR   EvolutionaryTrace; P02763; -.
DR   GenomeRNAi; 5004; -.
DR   NextBio; 19272; -.
DR   ArrayExpress; P02763; -.
DR   Bgee; P02763; -.
DR   CleanEx; HS_ORM1; -.
DR   Genevestigator; P02763; -.
DR   GermOnline; ENSG00000187681; Homo sapiens.
DR   GO; GO:0005615; C:extracellular space; TAS:ProtInc.
DR   GO; GO:0006953; P:acute-phase response; TAS:ProtInc.
DR   GO; GO:0002682; P:regulation of immune system process; IEA:InterPro.
DR   GO; GO:0006810; P:transport; IEA:UniProtKB-KW.
DR   Gene3D; 2.40.128.20; Calycin; 1.
DR   InterPro; IPR001500; A1A_glycop.
DR   InterPro; IPR012674; Calycin.
DR   InterPro; IPR011038; Calycin-like.
DR   InterPro; IPR000566; Lipocln_cytosolic_FA-bd_dom.
DR   PANTHER; PTHR11967; PTHR11967; 1.
DR   Pfam; PF00061; Lipocalin; 1.
DR   PIRSF; PIRSF036899; AGP; 1.
DR   PRINTS; PR00708; A1AGLPROTEIN.
DR   SUPFAM; SSF50814; Calycin; 1.
DR   PROSITE; PS00213; LIPOCALIN; FALSE_NEG.
PE   1: Evidence at protein level;
KW   3D-structure; Acute phase; Complete proteome;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein; Polymorphism;
KW   Pyrrolidone carboxylic acid; Reference proteome; Secreted; Signal;
KW   Transport.
FT   SIGNAL        1     18
FT   CHAIN        19    201       Alpha-1-acid glycoprotein 1.
FT                                /FTId=PRO_0000017860.
FT   MOD_RES      19     19       Pyrrolidone carboxylic acid.
FT   CARBOHYD     33     33       N-linked (GlcNAc...) (complex).
FT   CARBOHYD     56     56       N-linked (GlcNAc...).
FT   CARBOHYD     72     72       N-linked (GlcNAc...) (complex).
FT   CARBOHYD     93     93       N-linked (GlcNAc...).
FT   CARBOHYD    103    103       N-linked (GlcNAc...).
FT                                /FTId=CAR_000170.
FT   DISULFID     23    165
FT   DISULFID     90    183
FT   VARIANT      38     38       Q -> R (in allele ORM1*S).
FT                                /FTId=VAR_013840.
FT   VARIANT     167    167       R -> C (in dbSNP:rs3182034).
FT                                /FTId=VAR_056166.
FT   VARIANT     174    174       V -> M (in allele ORM1*F2;
FT                                dbSNP:rs1126801).
FT                                /FTId=VAR_013841.
FT   CONFLICT    170    170       K -> R (in Ref. 8; AAI43315).
FT   CONFLICT    182    182       Missing (in Ref. 10; AA sequence).
FT   CONFLICT    193    193       Missing (in Ref. 10; AA sequence).
FT   HELIX        24     26
FT   HELIX        33     39
FT   STRAND       41     52
FT   HELIX        53     59
FT   STRAND       62     72
FT   TURN         73     76
FT   STRAND       77     86
FT   STRAND       89    100
FT   TURN        101    104
FT   STRAND      105    110
FT   STRAND      113    121
FT   STRAND      127    132
FT   HELIX       137    139
FT   STRAND      141    149
FT   TURN        153    156
FT   HELIX       157    166
FT   HELIX       170    172
FT   HELIX       178    180
FT   HELIX       184    192
SQ   SEQUENCE   201 AA;  23512 MW;  63292233AD6EAD8B CRC64;
     MALSWVLTVL SLLPLLEAQI PLCANLVPVP ITNATLDQIT GKWFYIASAF RNEEYNKSVQ
     EIQATFFYFT PNKTEDTIFL REYQTRQDQC IYNTTYLNVQ RENGTISRYV GGQEHFAHLL
     ILRDTKTYML AFDVNDEKNW GLSVYADKPE TTKEQLGEFY EALDCLRIPK SDVVYTDWKK
     DKCEPLEKQH EKERKQEEGE S
//
ID   A1AT_HUMAN              Reviewed;         418 AA.
AC   P01009; A6PX14; B2RDQ8; Q0PVP5; Q13672; Q53XB8; Q5U0M1; Q7M4R2;
AC   Q86U18; Q86U19; Q96BF9; Q96ES1; Q9P1P0; Q9UCE6; Q9UCM3;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 3.
DT   28-NOV-2012, entry version 189.
DE   RecName: Full=Alpha-1-antitrypsin;
DE   AltName: Full=Alpha-1 protease inhibitor;
DE   AltName: Full=Alpha-1-antiproteinase;
DE   AltName: Full=Serpin A1;
DE   Contains:
DE     RecName: Full=Short peptide from AAT;
DE              Short=SPAAT;
DE   Flags: Precursor;
GN   Name=SERPINA1; Synonyms=AAT, PI; ORFNames=PRO0684, PRO2209;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   MEDLINE=84107980; PubMed=6319097;
RA   Bollen A., Herzog A., Cravador A., Herion P., Chuchana P.,
RA   van der Straten A., Loriau R., Jacobs P., van Elsen A.;
RT   "Cloning and expression in Escherichia coli of full-length
RT   complementary DNA coding for human alpha 1-antitrypsin.";
RL   DNA 2:255-264(1983).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=85047190; PubMed=6093867; DOI=10.1021/bi00316a003;
RA   Long G.L., Chandra T., Woo S.L.C., Davie E.W., Kurachi K.;
RT   "Complete sequence of the cDNA for human alpha 1-antitrypsin and the
RT   gene for the S variant.";
RL   Biochemistry 23:4828-4837(1984).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND MUTAGENESIS OF MET-382.
RX   MEDLINE=85036645; PubMed=6387509; DOI=10.1038/312077a0;
RA   Rosenberg S., Barr P.J., Najarian R.C., Hallewell R.A.;
RT   "Synthesis in yeast of a functional oxidation-resistant mutant of
RT   human alpha-antitrypsin.";
RL   Nature 312:77-80(1984).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   MEDLINE=85176977; PubMed=2985281; DOI=10.1016/S0092-8674(85)80026-X;
RA   Ciliberto G., Dente L., Cortese R.;
RT   "Cell-specific expression of a transfected human alpha 1-antitrypsin
RT   gene.";
RL   Cell 41:531-540(1985).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND CHARACTERIZATION OF VARIANT Z.
RX   MEDLINE=87057257; PubMed=3491072;
RA   Nukiwa T., Satoh K., Brantly M.L., Ogushi F., Fells G.A., Courtney M.,
RA   Crystal R.G.;
RT   "Identification of a second mutation in the protein-coding sequence of
RT   the Z type alpha 1-antitrypsin gene.";
RL   J. Biol. Chem. 261:15989-15994(1986).
RN   [6]
RP   ERRATUM.
RA   Nukiwa T., Satoh K., Brantly M.L., Ogushi F., Fells G.A., Courtney M.,
RA   Crystal R.G.;
RL   J. Biol. Chem. 262:10412-10412(1987).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ALA-237 AND
RP   ASP-400.
RC   TISSUE=Liver;
RX   PubMed=17650587;
RA   Shasany A.K., Shukla A.K., Darokar M.P., Saraiya M., Chaturvedi N.,
RA   Tewari L., Khanuja S.P.;
RT   "An alpha-1 antitrypsin genetic variant from India.";
RL   Indian J. Biochem. Biophys. 44:176-178(2007).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS TRP-172; ALA-237 AND
RP   LYS-366.
RC   TISSUE=Lymphocyte;
RA   Balduyck M., Porchet N., Aubert J.-P., Zerimech F., Douchain F.,
RA   Verchain S.;
RT   "Characterization of a new variant of alpha1 antitrypsin M Lille
RT   (p.Gly148Trp).";
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Fetal liver;
RA   Zhang C., Yu Y., Zhang S., Ouyang S., Luo L., Wei H., Zhou G.,
RA   Zhou W., Bi J., Zhang Y., Liu M., He F.;
RT   "Functional prediction of the coding sequences of 32 new genes deduced
RT   by analysis of cDNA clones from human fetal liver.";
RL   Submitted (DEC-1998) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3).
RC   TISSUE=Fetal liver, and Placenta;
RA   Li W.B., Gruber C., Jessee J., Polayes D.;
RT   "Full-length cDNA libraries and normalization.";
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Synovium;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   ALA-237.
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Colon, and Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-67; 196-255 AND 387-418.
RX   MEDLINE=82220035; PubMed=6979715; DOI=10.1038/297655a0;
RA   Leicht M., Long G.L., Chandra T., Kurachi K., Kidd V.J., Mace M. Jr.,
RA   Davie E.W., Woo S.L.C.;
RT   "Sequence homology and structural comparison between the chromosomal
RT   human alpha 1-antitrypsin and chicken ovalbumin genes.";
RL   Nature 297:655-659(1982).
RN   [15]
RP   PRELIMINARY PROTEIN SEQUENCE OF 25-418 (ISOFORM 1).
RA   Chan S.K.;
RT   "The covalent structure of human alpha1-protease inhibitor.";
RL   Fed. Proc. 41:1016-1016(1982).
RN   [16]
RP   PROTEIN SEQUENCE OF 25-418 (ISOFORM 1).
RX   MEDLINE=82220135; PubMed=7045697; DOI=10.1038/298329a0;
RA   Carrell R.W., Jeppsson J.-O., Laurell C.-B., Brennan S.O., Owen M.C.,
RA   Vaughan L., Boswell D.R.;
RT   "Structure and variation of human alpha 1-antitrypsin.";
RL   Nature 298:329-334(1982).
RN   [17]
RP   PROTEIN SEQUENCE OF 25-418 (ISOFORM 1), VARIANTS ABERRANT FORM
RP   190-GLY--ARG-198 AND VAL-288, AND FUNCTION.
RC   TISSUE=Blood;
RA   Sinha A.K., Girish G.V.;
RT   "Appearance of an aberrant form of alpha-antitrypsin in the
RT   circulation of chronic cigarette smokers and its effect on the insulin
RT   induced NO synthesis in blood platelets.";
RL   Submitted (AUG-2007) to UniProtKB.
RN   [18]
RP   PROTEIN SEQUENCE OF 25-39, AND FUNCTION.
RC   TISSUE=Ascites;
RX   MEDLINE=91310496; PubMed=1906855;
RA   Tanaka N., Sekiya S., Takamizawa H., Kato N., Moriyama Y.,
RA   Fujimura S.;
RT   "Characterization of a 54 kDa, alpha 1-antitrypsin-like protein
RT   isolated from ascitic fluid of an endometrial cancer patient.";
RL   Jpn. J. Cancer Res. 82:693-700(1991).
RN   [19]
RP   PROTEIN SEQUENCE OF 30-48 AND 248-257 (ISOFORMS 1/2/3), GLYCOSYLATION
RP   AT ASN-70; ASN-107 AND ASN-271, STRUCTURE OF CARBOHYDRATES,
RP   CYSTEINE-BINDING, AND MASS SPECTROMETRY.
RX   PubMed=16622833; DOI=10.1002/pmic.200500751;
RA   Kolarich D., Weber A., Turecek P.L., Schwarz H.P., Altmann F.;
RT   "Comprehensive glyco-proteomic analysis of human alpha1-antitrypsin
RT   and its charge isoforms.";
RL   Proteomics 6:3369-3380(2006).
RN   [20]
RP   PROTEIN SEQUENCE OF 47-66.
RC   TISSUE=Urine;
RX   MEDLINE=93312288; PubMed=8323530; DOI=10.1006/bbrc.1993.1731;
RA   Umekawa T., Kohri K., Amasaki N., Yamate T., Yoshida K., Yamamoto K.,
RA   Suzuki Y., Sinohara H., Kurita T.;
RT   "Sequencing of a urinary stone protein, identical to alpha-one
RT   antitrypsin, which lacks 22 amino acids.";
RL   Biochem. Biophys. Res. Commun. 193:1049-1053(1993).
RN   [21]
RP   PROTEIN SEQUENCE OF 50-63 AND 161-178 (ISOFORMS 1/2/3), AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Brain, and Cajal-Retzius cell;
RA   Lubec G., Afjehi-Sadat L.;
RL   Submitted (MAR-2007) to UniProtKB.
RN   [22]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 292-418 (ISOFORM 1).
RX   MEDLINE=86005469; PubMed=3876243; DOI=10.1016/0014-5793(85)81056-5;
RA   Riley J.H., Bathurst I.C., Edbrooke M.R., Carrell R.W., Craig R.K.;
RT   "Alpha 1-antitrypsin and serum albumin mRNA accumulation in normal,
RT   acute phase and ZZ human liver.";
RL   FEBS Lett. 189:361-366(1985).
RN   [23]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 350-418 (ISOFORM 1).
RX   MEDLINE=82082539; PubMed=7031661; DOI=10.1073/pnas.78.11.6826;
RA   Kurachi K., Chandra T., Friezner Degen S.J., White T.T.,
RA   Marchioro T.L., Woo S.L.C., Davie E.W.;
RT   "Cloning and sequence of cDNA coding for alpha 1-antitrypsin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 78:6826-6830(1981).
RN   [24]
RP   PROTEIN SEQUENCE OF 375-414, IDENTIFICATION OF SPAAT, FUNCTION, AND
RP   SUBCELLULAR LOCATION.
RC   TISSUE=Placenta;
RX   MEDLINE=93024095; PubMed=1406456;
RA   Niemann M.A., Narkates A.J., Miller E.J.;
RT   "Isolation and serine protease inhibitory activity of the 44-residue,
RT   C-terminal fragment of alpha 1-antitrypsin from human placenta.";
RL   Matrix 12:233-241(1992).
RN   [25]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 387-418 (ISOFORM 1).
RX   MEDLINE=85225507; PubMed=3873938;
RA   Coutelle C., Speer A., Rogers J., Kalsheker N., Humphries S.,
RA   Williamson R.;
RT   "Construction and partial characterization of a human liver cDNA
RT   library.";
RL   Biomed. Biochim. Acta 44:421-431(1985).
RN   [26]
RP   GLYCOSYLATION AT ASN-70 AND ASN-271.
RX   MEDLINE=22660472; PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [27]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70 AND ASN-271, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Bile;
RX   PubMed=15084671; DOI=10.1074/mcp.M400015-MCP200;
RA   Kristiansen T.Z., Bunkenborg J., Gronborg M., Molina H.,
RA   Thuluvath P.J., Argani P., Goggins M.G., Maitra A., Pandey A.;
RT   "A proteomic analysis of human bile.";
RL   Mol. Cell. Proteomics 3:715-728(2004).
RN   [28]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70 AND ASN-271, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [29]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70; ASN-107 AND ASN-271,
RP   AND MASS SPECTROMETRY.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [30]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70, AND MASS SPECTROMETRY.
RC   TISSUE=Platelet;
RX   PubMed=16263699; DOI=10.1074/mcp.M500324-MCP200;
RA   Lewandrowski U., Moebius J., Walter U., Sickmann A.;
RT   "Elucidation of N-glycosylation sites on human platelet proteins: a
RT   glycoproteomic approach.";
RL   Mol. Cell. Proteomics 5:226-233(2006).
RN   [31]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70; ASN-107 AND ASN-271,
RP   AND MASS SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [32]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70; ASN-107 AND ASN-271,
RP   STRUCTURE OF CARBOHYDRATES, AND MASS SPECTROMETRY.
RC   TISSUE=Cerebrospinal fluid;
RX   PubMed=19838169; DOI=10.1038/nmeth.1392;
RA   Nilsson J., Rueetschi U., Halim A., Hesse C., Carlsohn E.,
RA   Brinkmalm G., Larson G.;
RT   "Enrichment of glycopeptides for glycan structure and attachment site
RT   identification.";
RL   Nat. Methods 6:809-811(2009).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [34]
RP   GLYCOSYLATION AT ASN-70 AND ASN-271, STRUCTURE OF CARBOHYDRATES, AND
RP   MASS SPECTROMETRY.
RX   PubMed=22171320; DOI=10.1074/mcp.M111.013649;
RA   Halim A., Nilsson J., Ruetschi U., Hesse C., Larson G.;
RT   "Human urinary glycoproteomics; attachment site specific analysis of
RT   N-and O-linked glycosylations by CID and ECD.";
RL   Mol. Cell. Proteomics 0:0-0(2011).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS).
RX   MEDLINE=84292309; PubMed=6332197; DOI=10.1016/0022-2836(84)90298-5;
RA   Loebermann H., Tokuoka R., Deisenhofer J., Huber R.;
RT   "Human alpha 1-proteinase inhibitor. Crystal structure analysis of two
RT   crystal modifications, molecular model and preliminary analysis of the
RT   implications for function.";
RL   J. Mol. Biol. 177:531-556(1984).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS).
RX   MEDLINE=89221004; PubMed=2785270; DOI=10.1093/protein/2.6.407;
RA   Engh R., Loebermann H., Schneider M., Wiegand G., Huber R.,
RA   Laurell C.-B.;
RT   "The S variant of human alpha 1-antitrypsin, structure and
RT   implications for function and metabolism.";
RL   Protein Eng. 2:407-415(1989).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (3.46 ANGSTROMS) OF 25-418.
RX   MEDLINE=96128217; PubMed=8543039; DOI=10.1016/0014-5793(95)01331-8;
RA   Song H.K., Lee K.N., Kwon K.-S., Yu M.-H., Suh S.W.;
RT   "Crystal structure of an uncleaved alpha 1-antitrypsin reveals the
RT   conformation of its inhibitory reactive loop.";
RL   FEBS Lett. 377:150-154(1995).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 26-418.
RX   MEDLINE=96313123; PubMed=8756325; DOI=10.1038/nsb0896-676;
RA   Elliott P.R., Lomas D.A., Carrell R.W., Abrahams J.P.;
RT   "Inhibitory conformation of the reactive loop of alpha 1-
RT   antitrypsin.";
RL   Nat. Struct. Biol. 3:676-681(1996).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 45-418.
RX   MEDLINE=97094975; PubMed=8939743; DOI=10.1016/S0969-2126(96)00126-8;
RA   Ryu S.-E., Choi H.-J., Kwon K.-S., Lee K.N., Yu M.-H.;
RT   "The native strains in the hydrophobic core and flexible reactive loop
RT   of a serine protease inhibitor: crystal structure of an uncleaved
RT   alpha1-antitrypsin at 2.7 A.";
RL   Structure 4:1181-1192(1996).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 26-418.
RX   MEDLINE=98139957; PubMed=9466920; DOI=10.1006/jmbi.1997.1458;
RA   Elliott P.R., Abrahams J.P., Lomas D.A.;
RT   "Wild-type alpha 1-antitrypsin is in the canonical inhibitory
RT   conformation.";
RL   J. Mol. Biol. 275:419-425(1998).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 48-418 IN COMPLEX WITH BOVINE
RP   TRYPSIN.
RX   MEDLINE=20509356; PubMed=11057674; DOI=10.1038/35038119;
RA   Huntington J.A., Read R.J., Carrell R.W.;
RT   "Structure of a serpin-protease complex shows inhibition by
RT   deformation.";
RL   Nature 407:923-926(2000).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 44-418.
RX   MEDLINE=20178938; PubMed=10716194;
RA   Dunstone M.A., Dai W., Whisstock J.C., Rossjohn J., Pike R.N.,
RA   Feil S.C., Le Bonniec B.F., Parker M.W., Bottomley S.P.;
RT   "Cleaved antitrypsin polymers at atomic resolution.";
RL   Protein Sci. 9:417-420(2000).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS).
RX   MEDLINE=20386623; PubMed=10933492;
RA   Elliott P.R., Pei X.Y., Dafforn T.R., Lomas D.A.;
RT   "Topography of a 2.0 A structure of alpha1-antitrypsin reveals targets
RT   for rational drug design to prevent conformational disease.";
RL   Protein Sci. 9:1274-1281(2000).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 25-418.
RX   MEDLINE=21103710; PubMed=11178897; DOI=10.1006/jmbi.2000.4357;
RA   Kim S.-J., Woo J.-R., Seo E.J., Yu M.-H., Ryu S.-E.;
RT   "A 2.1 A resolution structure of an uncleaved alpha(1)-antitrypsin
RT   shows variability of the reactive center and other loops.";
RL   J. Mol. Biol. 306:109-119(2001).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 25-418.
RX   MEDLINE=22336385; PubMed=12244055; DOI=10.1074/jbc.M207682200;
RA   Im H., Woo M.-S., Hwang K.Y., Yu M.-H.;
RT   "Interactions causing the kinetic trap in serpin protein folding.";
RL   J. Biol. Chem. 277:46347-46354(2002).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 26-418 OF VARIANT PITTSBURGH
RP   ARG-382.
RX   MEDLINE=22863108; PubMed=12860985; DOI=10.1074/jbc.M305195200;
RA   Dementiev A., Simonovic M., Volz K., Gettins P.G.;
RT   "Canonical inhibitor-like interactions explain reactivity of alpha1-
RT   proteinase inhibitor Pittsburgh and antithrombin with proteinases.";
RL   J. Biol. Chem. 278:37881-37887(2003).
RN   [47]
RP   REVIEW.
RX   MEDLINE=89352843; PubMed=2669992; DOI=10.1007/BF01115992;
RA   Kalsheker N.;
RT   "Alpha 1-antitrypsin: structure, function and molecular biology of the
RT   gene.";
RL   Biosci. Rep. 9:129-138(1989).
RN   [48]
RP   REVIEW.
RX   MEDLINE=91315455; PubMed=1859394; DOI=10.1002/bies.950130404;
RA   Wu Y., Foreman R.C.;
RT   "The molecular genetics of alpha 1 antitrypsin deficiency.";
RL   Bioessays 13:163-169(1991).
RN   [49]
RP   CHARACTERIZATION OF VARIANT M2.
RX   MEDLINE=88324438; PubMed=2901226;
RA   Nukiwa T., Brantly M.L., Ogushi F., Fells G.A., Crystal R.G.;
RT   "Characterization of the gene and protein of the common alpha 1-
RT   antitrypsin normal M2 allele.";
RL   Am. J. Hum. Genet. 43:322-330(1988).
RN   [50]
RP   VARIANT M3 ASP-400.
RX   MEDLINE=90368097; PubMed=2394452; DOI=10.1007/BF00206766;
RA   Graham A., Hayes K., Weidinger S., Newton C.R., Markham A.F.,
RA   Kalsheker N.A.;
RT   "Characterisation of the alpha-1-antitrypsin M3 gene, a normal
RT   variant.";
RL   Hum. Genet. 85:381-382(1990).
RN   [51]
RP   VARIANT F CYS-247.
RX   MEDLINE=91241132; PubMed=2035534;
RA   Okayama H., Brantly M., Holmes M., Crystal R.G.;
RT   "Characterization of the molecular basis of the alpha 1-antitrypsin F
RT   allele.";
RL   Am. J. Hum. Genet. 48:1154-1158(1991).
RN   [52]
RP   VARIANT M-HEERLEN LEU-393.
RX   MEDLINE=89154435; PubMed=2784123; DOI=10.1007/BF00279001;
RA   Hofker M.H., Nukiwa T., van Paassen H.M.B., Nelen M., Kramps J.A.,
RA   Klasen E.C., Frants R.R., Crystal R.G.;
RT   "A Pro-->Leu substitution in codon 369 of the alpha-1-antitrypsin
RT   deficiency variant PI M-Heerlen.";
RL   Hum. Genet. 81:264-268(1989).
RN   [53]
RP   VARIANT M-MALTON PHE-75 DEL.
RX   MEDLINE=89270478; PubMed=2786335;
RA   Fraizer G.C., Harrold T.R., Hofker M.H., Cox D.W.;
RT   "In-frame single codon deletion in the M-Malton deficiency allele of
RT   alpha 1-antitrypsin.";
RL   Am. J. Hum. Genet. 44:894-902(1989).
RN   [54]
RP   VARIANT M-MINERAL SPRINGS GLU-91.
RX   MEDLINE=90097863; PubMed=1967187;
RA   Curiel D.T., Vogelmeier C., Hubbard R.C., Stier L.E., Crystal R.G.;
RT   "Molecular basis of alpha 1-antitrypsin deficiency and emphysema
RT   associated with the alpha 1-antitrypsin M-Mineral springs allele.";
RL   Mol. Cell. Biol. 10:47-56(1990).
RN   [55]
RP   VARIANT M-NICHINAN PHE-75 DEL.
RX   MEDLINE=90178096; PubMed=2309708;
RA   Matsunaga E., Shiokawa S., Nakamura H., Maruyama T., Tsuda K.,
RA   Fukumaki Y.;
RT   "Molecular analysis of the gene of the alpha 1-antitrypsin deficiency
RT   variant, M-Nichinan.";
RL   Am. J. Hum. Genet. 46:602-612(1990).
RN   [56]
RP   VARIANT M-PROCIDA PRO-65.
RX   MEDLINE=89008457; PubMed=3262617;
RA   Takahashi H., Nukiwa T., Satoh K., Ogushi F., Brantly M., Fells G.,
RA   Stier L., Courtney M., Crystal R.G.;
RT   "Characterization of the gene and protein of the alpha 1-antitrypsin
RT   'deficiency' allele M-Procida.";
RL   J. Biol. Chem. 263:15528-15534(1988).
RN   [57]
RP   VARIANT P-DUARTE VAL-280.
RX   MEDLINE=93372875; PubMed=8364590; DOI=10.1002/humu.1380020311;
RA   Hildesheim J., Kinsley G., Bissell M., Pierce J., Brantly M.;
RT   "Genetic diversity from a limited repertoire of mutations on different
RT   common allelic backgrounds: alpha 1-antitrypsin deficiency variant P-
RT   Duarte.";
RL   Hum. Mutat. 2:221-228(1993).
RN   [58]
RP   INVOLVEMENT OF VARIANT PITTSBURGH ARG-382 IN BLEEDING DIATHESIS.
RX   MEDLINE=83297520; PubMed=6604220;
RA   Owen M.C., Brennan S.O., Lewis J.H., Carrell R.W.;
RT   "Mutation of antitrypsin to antithrombin. Alpha 1-antitrypsin
RT   Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder.";
RL   N. Engl. J. Med. 309:694-698(1983).
RN   [59]
RP   INVOLVEMENT IN A1ATD, AND VARIANT S-IIYAMA PHE-77.
RX   MEDLINE=91286296; PubMed=1905728;
RA   Seyama K., Nukiwa T., Takabe K., Takahashi H., Miyake K., Kira S.;
RT   "Siiyama (serine 53 (TCC) to phenylalanine 53 (TTC)). A new alpha 1-
RT   antitrypsin-deficient variant with mutation on a predicted conserved
RT   residue of the serpin backbone.";
RL   J. Biol. Chem. 266:12627-12632(1991).
RN   [60]
RP   VARIANT V-MUNICH ALA-26.
RX   MEDLINE=90196014; PubMed=2316526;
RA   Holmes M.D., Brantly M.L., Curiel D.T., Weidinger S., Crystal R.G.;
RT   "Characterization of the normal alpha 1-antitrypsin allele V-Munich: a
RT   variant associated with a unique protein isoelectric focusing
RT   pattern.";
RL   Am. J. Hum. Genet. 46:810-816(1990).
RN   [61]
RP   INVOLVEMENT IN A1ATD, AND VARIANT W-BETHESDA THR-360.
RX   MEDLINE=90358792; PubMed=2390072; DOI=10.1016/0006-291X(90)90493-7;
RA   Holmes M.D., Brantly M.L., Fells G.A., Crystal R.G.;
RT   "Alpha 1-antitrypsin W-Bethesda: molecular basis of an unusual alpha
RT   1-antitrypsin deficiency variant.";
RL   Biochem. Biophys. Res. Commun. 170:1013-1020(1990).
RN   [62]
RP   VARIANT Z-AUGSBURG LYS-366.
RX   MEDLINE=90252805; PubMed=2339709;
RA   Faber J.-P., Weidinger S., Olek K.;
RT   "Sequence data of the rare deficient alpha 1-antitrypsin variant PI
RT   Zaugsburg.";
RL   Am. J. Hum. Genet. 46:1158-1162(1990).
RN   [63]
RP   INVOLVEMENT IN A1ATD, AND VARIANTS Z-WREXHAM LEU-4 AND Q0-NEWPORT
RP   SER-139.
RX   MEDLINE=91033789; PubMed=2227940; DOI=10.1007/BF00194233;
RA   Graham A., Kalsheker N.A., Bamforth F.J., Newton C.R., Markham A.F.;
RT   "Molecular characterisation of two alpha-1-antitrypsin deficiency
RT   variants: proteinase inhibitor (Pi) Null(Newport) (Gly115-->Ser) and
RT   (Pi) Z Wrexham (Ser-19-->Leu).";
RL   Hum. Genet. 85:537-540(1990).
RN   [64]
RP   VARIANTS P-CARDIFF VAL-280; I CYS-63 AND M-MALTON PHE-75 DEL.
RX   MEDLINE=90109164; PubMed=2606478; DOI=10.1007/BF00210671;
RA   Graham A., Kalsheker N.A., Newton C.R., Bamforth F.J., Powell S.J.,
RA   Markham A.F.;
RT   "Molecular characterisation of three alpha-1-antitrypsin deficiency
RT   variants: proteinase inhibitor (Pi) nullcardiff (Asp256-->Val); PiM-
RT   Malton (Phe51-->deletion) and PiI (Arg39-->Cys).";
RL   Hum. Genet. 84:55-58(1989).
RN   [65]
RP   VARIANT QO-LUDWIGSHAFEN ASN-116.
RX   MEDLINE=91072661; PubMed=2254451; DOI=10.1172/JCI114919;
RA   Fraizer G.C., Siewertsen M.A., Hofker M.H., Brubacher M.G., Cox D.W.;
RT   "A null deficiency allele of alpha 1-antitrypsin, QO-Ludwigshafen,
RT   with altered tertiary structure.";
RL   J. Clin. Invest. 86:1878-1884(1990).
RN   [66]
RP   VARIANTS.
RX   MEDLINE=95067973; PubMed=7977369;
RA   Faber J.-P., Poller W., Weidinger S., Kirchgesser M., Schwaab R.,
RA   Bidlingmaier F., Olek K.;
RT   "Identification and DNA sequence analysis of 15 new alpha 1-
RT   antitrypsin variants, including two PI*Q0 alleles and one deficient
RT   PI*M allele.";
RL   Am. J. Hum. Genet. 55:1113-1121(1994).
RN   [67]
RP   VARIANT Z-BRISTOL MET-109.
RX   MEDLINE=98120621; PubMed=9459000; DOI=10.1017/S0003480097006404;
RA   Lovegrove J.U., Jeremiah S., Gillett G.T., Temple I.K., Povey S.,
RA   Whitehouse D.B.;
RT   "A new alpha 1-antitrypsin mutation, Thr-Met 85, (PI ZBristol)
RT   associated with novel electrophoretic properties.";
RL   Ann. Hum. Genet. 61:385-391(1997).
RN   [68]
RP   VARIANTS Y-BARCELONA VAL-280 AND HIS-415.
RX   PubMed=10651487;
RA   Jardi R., Rodriguez F., Miravitlles M., Vidal R., Cotrina M., Quer J.,
RA   Pascual C., Weidinger S.;
RT   "Identification and molecular charaterization of the new alpha-1-
RT   antitrypsin deficient allele PI YBarcelona (Asp256Val and
RT   Pro391His).";
RL   Hum. Mutat. 12:213-213(1998).
RN   [69]
RP   VARIANT SAO TOME HIS-386.
RA   Seixas S., Trovoada M.J., Santos M.T., Rocha J.;
RT   "A novel alpha-1-antitrypsin P362H variant found in a population
RT   sample from Sao Tome e Principe (Gulf of Guinea, West Africa).";
RL   Hum. Mutat. 13:414-414(1999).
RN   [70]
RP   VARIANT BASQUE ARG-305 DEL.
RX   MEDLINE=20081076; PubMed=10612848;
RX   DOI=10.1002/(SICI)1098-1004(200001)15:1<121::AID-HUMU37>3.0.CO;2-U;
RA   Seixas S., Garcia O., Amorim A., Rocha J.;
RT   "A novel alpha-1-antitrypsin r281del variant found in a population
RT   sample from the Basque country.";
RL   Hum. Mutat. 15:121-122(2000).
CC   -!- FUNCTION: Inhibitor of serine proteases. Its primary target is
CC       elastase, but it also has a moderate affinity for plasmin and
CC       thrombin. Irreversibly inhibits trypsin, chymotrypsin and
CC       plasminogen activator. The aberrant form inhibits insulin-induced
CC       NO synthesis in platelets, decreases coagulation time and has
CC       proteolytic activity against insulin and plasmin.
CC   -!- FUNCTION: Short peptide from AAT (SPAAT) is a reversible
CC       chymotrypsin inhibitor. It also inhibits elastase, but not
CC       trypsin. Its major physiological function is the protection of the
CC       lower respiratory tract against proteolytic destruction by human
CC       leukocyte elastase (HLE).
CC   -!- INTERACTION:
CC       P00760:- (xeno); NbExp=3; IntAct=EBI-986224, EBI-986385;
CC       P00772:CELA1 (xeno); NbExp=2; IntAct=EBI-986224, EBI-986248;
CC       P71213:espB (xeno); NbExp=3; IntAct=EBI-986224, EBI-2615322;
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- SUBCELLULAR LOCATION: Short peptide from AAT: Secreted,
CC       extracellular space, extracellular matrix.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P01009-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P01009-2; Sequence=VSP_028889;
CC         Note=No experimental confirmation available;
CC       Name=3;
CC         IsoId=P01009-3; Sequence=VSP_028890;
CC         Note=No experimental confirmation available. May be produced at
CC         very low levels due to a premature stop codon in the mRNA,
CC         leading to nonsense-mediated mRNA decay;
CC   -!- TISSUE SPECIFICITY: Plasma.
CC   -!- DOMAIN: The reactive center loop (RCL) extends out from the body
CC       of the protein and directs binding to the target protease. The
CC       protease cleaves the serpin at the reactive site within the RCL,
CC       establishing a covalent linkage between the carboxyl group of the
CC       serpin reactive site and the serine hydroxyl of the protease. The
CC       resulting inactive serpin-protease complex is highly stable.
CC   -!- PTM: N-glycosylated. Differential glycosylation produces a number
CC       of isoforms. N-linked glycan at Asn-107 is alternatively di-
CC       antennary, tri-antennary or tetra-antennary. The glycan at Asn-70
CC       is di-antennary with trace amounts of tri-antennary. Glycan at
CC       Asn-271 is exclusively di-antennary. Structure of glycans at Asn-
CC       70 and Asn-271 is Hex5HexNAc4. The structure of the antennae is
CC       Neu5Ac(alpha1-6)Gal(beta1-4)GlcNAc attached to the core structure
CC       Man(alpha1-6)[Man(alpha1-3)]Man(beta1-4)GlcNAc(beta1-4)GlcNAc.
CC       Some antennae are fucosylated, which forms a Lewis-X determinant.
CC   -!- PTM: Proteolytic processing may yield the truncated form that
CC       ranges from Asp-30 to Lys-418.
CC   -!- POLYMORPHISM: The sequence shown is that of the M1V allele which
CC       is the most common form of PI (44 to 49%). Other frequent alleles
CC       are: M1A 20 to 23%; M2 10 to 11%; M3 14 to 19%.
CC   -!- DISEASE: Defects in SERPINA1 are the cause of alpha-1-antitrypsin
CC       deficiency (A1ATD) [MIM:613490]. A disorder whose most common
CC       manifestation is emphysema, which becomes evident by the third to
CC       fourth decade. A less common manifestation of the deficiency is
CC       liver disease, which occurs in children and adults, and may result
CC       in cirrhosis and liver failure. Environmental factors,
CC       particularly cigarette smoking, greatly increase the risk of
CC       emphysema at an earlier age.
CC   -!- MISCELLANEOUS: The aberrant form is found in the plasma of chronic
CC       smokers, and persists after smoking is ceased. It can still be
CC       found ten years after smoking has ceased.
CC   -!- SIMILARITY: Belongs to the serpin family.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAD62334.1; Type=Erroneous initiation; Note=Translation N-terminally shortened;
CC       Sequence=CAD62585.1; Type=Erroneous initiation; Note=Translation N-terminally shortened;
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/SERPINA1";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Alpha-1 antitrypsin entry;
CC       URL="http://en.wikipedia.org/wiki/Alpha_1-antitrypsin";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; K01396; AAB59375.1; -; mRNA.
DR   EMBL; K02212; AAB59495.1; -; Genomic_DNA.
DR   EMBL; X01683; CAA25838.1; -; mRNA.
DR   EMBL; M11465; AAA51546.1; -; mRNA.
DR   EMBL; J02619; AAA51547.1; -; Genomic_DNA.
DR   EMBL; DQ682455; ABG73380.1; -; mRNA.
DR   EMBL; AM048838; CAJ15161.1; -; Genomic_DNA.
DR   EMBL; AF113676; AAF29581.1; -; mRNA.
DR   EMBL; AF130068; AAG35496.1; -; mRNA.
DR   EMBL; BX161449; CAD61914.1; -; mRNA.
DR   EMBL; BX247968; CAD62306.1; -; mRNA.
DR   EMBL; BX248002; CAD62334.1; ALT_INIT; mRNA.
DR   EMBL; BX248257; CAD62585.1; ALT_INIT; mRNA.
DR   EMBL; AK315637; BAG38005.1; -; mRNA.
DR   EMBL; BT019455; AAV38262.1; -; mRNA.
DR   EMBL; BC011991; AAH11991.1; -; mRNA.
DR   EMBL; BC015642; AAH15642.1; -; mRNA.
DR   EMBL; J00064; AAB59369.1; -; Genomic_DNA.
DR   EMBL; J00066; AAB59370.1; -; Genomic_DNA.
DR   EMBL; J00065; AAB59370.1; JOINED; Genomic_DNA.
DR   EMBL; J00067; AAB59371.1; -; Genomic_DNA.
DR   EMBL; X02920; CAA26677.1; -; mRNA.
DR   EMBL; V00496; CAA23755.1; -; mRNA.
DR   EMBL; M26123; AAA51545.1; -; mRNA.
DR   IPI; IPI00553177; -.
DR   IPI; IPI00790784; -.
DR   IPI; IPI00869004; -.
DR   PIR; A21853; ITHU.
DR   PIR; A61391; A61391.
DR   RefSeq; NP_000286.3; NM_000295.4.
DR   RefSeq; NP_001002235.1; NM_001002235.2.
DR   RefSeq; NP_001002236.1; NM_001002236.2.
DR   RefSeq; NP_001121172.1; NM_001127700.1.
DR   RefSeq; NP_001121173.1; NM_001127701.1.
DR   RefSeq; NP_001121174.1; NM_001127702.1.
DR   RefSeq; NP_001121175.1; NM_001127703.1.
DR   RefSeq; NP_001121176.1; NM_001127704.1.
DR   RefSeq; NP_001121177.1; NM_001127705.1.
DR   RefSeq; NP_001121178.1; NM_001127706.1.
DR   RefSeq; NP_001121179.1; NM_001127707.1.
DR   UniGene; Hs.525557; -.
DR   PDB; 1ATU; X-ray; 2.70 A; A=45-418.
DR   PDB; 1D5S; X-ray; 3.00 A; A=44-377, B=378-418.
DR   PDB; 1EZX; X-ray; 2.60 A; A=48-382, B=383-418.
DR   PDB; 1HP7; X-ray; 2.10 A; A=25-418.
DR   PDB; 1IZ2; X-ray; 2.20 A; A=25-418.
DR   PDB; 1KCT; X-ray; 3.46 A; A=25-418.
DR   PDB; 1OO8; X-ray; 2.65 A; A=26-418.
DR   PDB; 1OPH; X-ray; 2.30 A; A=26-418.
DR   PDB; 1PSI; X-ray; 2.92 A; A=26-418.
DR   PDB; 1QLP; X-ray; 2.00 A; A=26-418.
DR   PDB; 1QMB; X-ray; 2.60 A; A=49-376, B=377-418.
DR   PDB; 2D26; X-ray; 3.30 A; A=26-382, B=383-418.
DR   PDB; 2QUG; X-ray; 2.00 A; A=25-418.
DR   PDB; 3CWL; X-ray; 2.44 A; A=25-418.
DR   PDB; 3CWM; X-ray; 2.51 A; A=25-418.
DR   PDB; 3DRM; X-ray; 2.20 A; A=26-418.
DR   PDB; 3DRU; X-ray; 3.20 A; A/B/C=26-418.
DR   PDB; 3NDD; X-ray; 1.50 A; A=46-372, B=383-418.
DR   PDB; 3NDF; X-ray; 2.70 A; A=46-381, B=383-418.
DR   PDB; 3NE4; X-ray; 1.81 A; A=1-418.
DR   PDB; 3T1P; X-ray; 3.90 A; A=48-418.
DR   PDB; 7API; X-ray; 3.00 A; A=36-382, B=383-418.
DR   PDB; 8API; X-ray; 3.10 A; A=36-382, B=383-418.
DR   PDB; 9API; X-ray; 3.00 A; A=36-382, B=383-418.
DR   PDBsum; 1ATU; -.
DR   PDBsum; 1D5S; -.
DR   PDBsum; 1EZX; -.
DR   PDBsum; 1HP7; -.
DR   PDBsum; 1IZ2; -.
DR   PDBsum; 1KCT; -.
DR   PDBsum; 1OO8; -.
DR   PDBsum; 1OPH; -.
DR   PDBsum; 1PSI; -.
DR   PDBsum; 1QLP; -.
DR   PDBsum; 1QMB; -.
DR   PDBsum; 2D26; -.
DR   PDBsum; 2QUG; -.
DR   PDBsum; 3CWL; -.
DR   PDBsum; 3CWM; -.
DR   PDBsum; 3DRM; -.
DR   PDBsum; 3DRU; -.
DR   PDBsum; 3NDD; -.
DR   PDBsum; 3NDF; -.
DR   PDBsum; 3NE4; -.
DR   PDBsum; 3T1P; -.
DR   PDBsum; 7API; -.
DR   PDBsum; 8API; -.
DR   PDBsum; 9API; -.
DR   ProteinModelPortal; P01009; -.
DR   SMR; P01009; 48-417.
DR   DIP; DIP-35493N; -.
DR   IntAct; P01009; 15.
DR   MINT; MINT-365327; -.
DR   STRING; P01009; -.
DR   MEROPS; I04.001; -.
DR   GlycoSuiteDB; P01009; -.
DR   PhosphoSite; P01009; -.
DR   DMDM; 1703025; -.
DR   Cornea-2DPAGE; P01009; -.
DR   DOSAC-COBS-2DPAGE; P01009; -.
DR   OGP; P01009; -.
DR   REPRODUCTION-2DPAGE; IPI00553177; -.
DR   REPRODUCTION-2DPAGE; P01009; -.
DR   Siena-2DPAGE; P01009; -.
DR   SWISS-2DPAGE; P01009; -.
DR   UCD-2DPAGE; P01009; -.
DR   PaxDb; P01009; -.
DR   PRIDE; P01009; -.
DR   DNASU; 5265; -.
DR   Ensembl; ENST00000355814; ENSP00000348068; ENSG00000197249.
DR   Ensembl; ENST00000393087; ENSP00000376802; ENSG00000197249.
DR   Ensembl; ENST00000393088; ENSP00000376803; ENSG00000197249.
DR   Ensembl; ENST00000402629; ENSP00000386094; ENSG00000197249.
DR   Ensembl; ENST00000404814; ENSP00000385960; ENSG00000197249.
DR   Ensembl; ENST00000437397; ENSP00000408474; ENSG00000197249.
DR   Ensembl; ENST00000440909; ENSP00000390299; ENSG00000197249.
DR   Ensembl; ENST00000448921; ENSP00000416066; ENSG00000197249.
DR   Ensembl; ENST00000449399; ENSP00000416354; ENSG00000197249.
DR   Ensembl; ENST00000489769; ENSP00000451525; ENSG00000197249.
DR   GeneID; 5265; -.
DR   KEGG; hsa:5265; -.
DR   UCSC; uc001ycx.4; human.
DR   UCSC; uc001yda.1; human.
DR   CTD; 5265; -.
DR   GeneCards; GC14M094843; -.
DR   HGNC; HGNC:8941; SERPINA1.
DR   HPA; CAB013211; -.
DR   HPA; CAB016648; -.
DR   HPA; HPA000927; -.
DR   HPA; HPA001292; -.
DR   MIM; 107400; gene.
DR   MIM; 613490; phenotype.
DR   neXtProt; NX_P01009; -.
DR   Orphanet; 60; Alpha-1 antitrypsin deficiency.
DR   Orphanet; 178396; Hemorrhagic disease due to alpha-1 antitrypsin Pittsburgh mutation.
DR   PharmGKB; PA35509; -.
DR   eggNOG; COG4826; -.
DR   HOVERGEN; HBG005957; -.
DR   InParanoid; P01009; -.
DR   KO; K03984; -.
DR   OMA; PMMNRLG; -.
DR   OrthoDB; EOG4FR0S4; -.
DR   PhylomeDB; P01009; -.
DR   Pathway_Interaction_DB; hnf3apathway; FOXA1 transcription factor network.
DR   Reactome; REACT_604; Hemostasis.
DR   DrugBank; DB00058; Alpha-1-proteinase inhibitor.
DR   EvolutionaryTrace; P01009; -.
DR   GenomeRNAi; 5265; -.
DR   NextBio; 20336; -.
DR   PMAP-CutDB; P01009; -.
DR   ArrayExpress; P01009; -.
DR   Bgee; P01009; -.
DR   Genevestigator; P01009; -.
DR   GermOnline; ENSG00000197249; Homo sapiens.
DR   GO; GO:0005615; C:extracellular space; IMP:UniProtKB.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0004867; F:serine-type endopeptidase inhibitor activity; NAS:UniProtKB.
DR   GO; GO:0006953; P:acute-phase response; IEA:UniProtKB-KW.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0030162; P:regulation of proteolysis; IBA:RefGenome.
DR   GO; GO:0046687; P:response to chromate; IEA:Compara.
DR   GO; GO:0034097; P:response to cytokine stimulus; IEA:Compara.
DR   GO; GO:0032355; P:response to estradiol stimulus; IEA:Compara.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Compara.
DR   GO; GO:0010288; P:response to lead ion; IEA:Compara.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Compara.
DR   GO; GO:0033986; P:response to methanol; IEA:Compara.
DR   GO; GO:0014070; P:response to organic cyclic compound; IEA:Compara.
DR   GO; GO:0034014; P:response to triglyceride; IEA:Compara.
DR   InterPro; IPR023795; Protease_inhib_I4_serpin_CS.
DR   InterPro; IPR023796; Serpin_dom.
DR   InterPro; IPR000215; Serpin_fam.
DR   PANTHER; PTHR11461; PTHR11461; 1.
DR   Pfam; PF00079; Serpin; 1.
DR   SMART; SM00093; SERPIN; 1.
DR   SUPFAM; SSF56574; Prot_inh_serpin; 1.
DR   PROSITE; PS00284; SERPIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acute phase; Alternative splicing; Blood coagulation;
KW   Complete proteome; Direct protein sequencing; Extracellular matrix;
KW   Glycoprotein; Hemostasis; Polymorphism; Protease inhibitor;
KW   Reference proteome; Secreted; Serine protease inhibitor; Signal.
FT   SIGNAL        1     24
FT   CHAIN        25    418       Alpha-1-antitrypsin.
FT                                /FTId=PRO_0000032377.
FT   PEPTIDE     375    418       Short peptide from AAT.
FT                                /FTId=PRO_0000364030.
FT   REGION      368    392       RCL.
FT   SITE        382    383       Reactive bond.
FT   MOD_RES     256    256       S-cysteinyl cysteine.
FT   CARBOHYD     70     70       N-linked (GlcNAc...) (complex).
FT   CARBOHYD    107    107       N-linked (GlcNAc...) (complex).
FT   CARBOHYD    271    271       N-linked (GlcNAc...) (complex).
FT   VAR_SEQ     307    418       Missing (in isoform 3).
FT                                /FTId=VSP_028890.
FT   VAR_SEQ     356    418       AVHKAVLTIDEKGTEAAGAMFLEAIPMSIPPEVKFNKPFVF
FT                                LMIEQNTKSPLFMGKVVNPTQK -> VRSP (in
FT                                isoform 2).
FT                                /FTId=VSP_028889.
FT   VARIANT       4      4       S -> L (in Z-Wrexham).
FT                                /FTId=VAR_006978.
FT   VARIANT      26     26       D -> A (in V-Munich).
FT                                /FTId=VAR_006979.
FT   VARIANT      37     37       T -> A (in dbSNP:rs11558262).
FT                                /FTId=VAR_051938.
FT   VARIANT      58     58       A -> T (in M5-Karlsruhe).
FT                                /FTId=VAR_006980.
FT   VARIANT      63     63       R -> C (in I; dbSNP:rs28931570).
FT                                /FTId=VAR_006981.
FT   VARIANT      65     65       L -> P (in M-Procida; dbSNP:rs28931569).
FT                                /FTId=VAR_006982.
FT   VARIANT      69     69       S -> F (in M6-Bonn).
FT                                /FTId=VAR_006983.
FT   VARIANT      75     75       Missing (in M-Malton, M-Nichinan and M-
FT                                Palermo; associated with very low serum
FT                                levels of AAT; homozygosity for allele M-
FT                                Malton may be associated with a risk for
FT                                chronic emphysema or infantile liver
FT                                cirrhosis).
FT                                /FTId=VAR_006984.
FT   VARIANT      77     77       S -> F (in S-Iiyama; dbSNP:rs55819880).
FT                                /FTId=VAR_006985.
FT   VARIANT      84     84       A -> T (in M6-Passau).
FT                                /FTId=VAR_006986.
FT   VARIANT      91     91       G -> E (in M-Mineral springs; causes
FT                                reduced AAT secretion; dbSNP:rs28931568).
FT                                /FTId=VAR_006987.
FT   VARIANT      92     92       T -> I (in QO-Lisbon; deficient AAT with
FT                                very low serum levels).
FT                                /FTId=VAR_006988.
FT   VARIANT     109    109       T -> M (in Z-Bristol; deficient AA;
FT                                disrupts the N-glycosylation site N-107).
FT                                /FTId=VAR_011620.
FT   VARIANT     112    112       P -> T (in M5-Berlin).
FT                                /FTId=VAR_006989.
FT   VARIANT     116    116       I -> N (in QO-Ludwigshafen;
FT                                dbSNP:rs28931572).
FT                                /FTId=VAR_006990.
FT   VARIANT     125    125       R -> H (in M2; associated with D-400;
FT                                dbSNP:rs709932).
FT                                /FTId=VAR_006991.
FT   VARIANT     139    139       G -> S (in QO-Newport; dbSNP:rs11558261).
FT                                /FTId=VAR_006992.
FT   VARIANT     172    172       G -> R (in V and M-Nichinan).
FT                                /FTId=VAR_006993.
FT   VARIANT     172    172       G -> W (in M2-Obernburg).
FT                                /FTId=VAR_006994.
FT   VARIANT     180    180       Q -> E (in L-Frankfurt).
FT                                /FTId=VAR_006995.
FT   VARIANT     190    198       QGKIVDLVK -> GFQNAILVR (in Aberrant
FT                                form).
FT                                /FTId=VAR_036746.
FT   VARIANT     228    228       E -> K (in X).
FT                                /FTId=VAR_006996.
FT   VARIANT     237    237       V -> A (in M1A and Z; associated with K-
FT                                366 in Z; dbSNP:rs6647).
FT                                /FTId=VAR_006997.
FT   VARIANT     247    247       R -> C (in F; dbSNP:rs28929470).
FT                                /FTId=VAR_006998.
FT   VARIANT     280    280       D -> V (in P-Duarte/P-Cardiff/P-Lowell;
FT                                associated with H-415 in Y-Barcelona;
FT                                dbSNP:rs28929472).
FT                                /FTId=VAR_006999.
FT   VARIANT     288    288       E -> V (in S and T; dbSNP:rs17580).
FT                                /FTId=VAR_007000.
FT   VARIANT     305    305       Missing (in Basque).
FT                                /FTId=VAR_009216.
FT   VARIANT     354    354       S -> F (in S-Munich).
FT                                /FTId=VAR_007001.
FT   VARIANT     360    360       A -> T (in W-Bethesda; dbSNP:rs1802959).
FT                                /FTId=VAR_007002.
FT   VARIANT     365    365       D -> N (in P-St.Albans/P-Donauwoerth).
FT                                /FTId=VAR_007003.
FT   VARIANT     366    366       E -> K (in Z/Z-Augsburg/Z-Tun; associated
FT                                with A-237 in Z; dbSNP:rs28929474).
FT                                /FTId=VAR_007004.
FT   VARIANT     382    382       M -> R (in Pittsburgh; has antithrombin
FT                                activity; causes fatal bleeding
FT                                diathesis).
FT                                /FTId=VAR_007005.
FT   VARIANT     386    386       P -> H (in Sao Tome).
FT                                /FTId=VAR_007006.
FT   VARIANT     386    386       P -> T (in L-Offenbach).
FT                                /FTId=VAR_007007.
FT   VARIANT     387    387       E -> K (in Christchurch).
FT                                /FTId=VAR_007008.
FT   VARIANT     393    393       P -> L (in M-Heerlen).
FT                                /FTId=VAR_007009.
FT   VARIANT     400    400       E -> D (in M2 and M3; associated with H-
FT                                125 in M2; dbSNP:rs1303).
FT                                /FTId=VAR_007010.
FT   VARIANT     415    415       P -> H (in Y-Barcelona; associated with
FT                                V-280).
FT                                /FTId=VAR_007011.
FT   MUTAGEN     382    382       M->V: Oxidation-resistant inhibitor of
FT                                therapeutic importance.
FT   CONFLICT     12     12       Missing (in Ref. 4; AAA51546).
FT   CONFLICT     23     23       L -> P (in Ref. 11; BAG38005).
FT   CONFLICT     26     26       D -> H (in Ref. 18; AA sequence).
FT   CONFLICT     39     39       H -> L (in Ref. 18; AA sequence).
FT   CONFLICT     61     61       L -> P (in Ref. 9; AAF29581).
FT   CONFLICT     96     96       T -> A (in Ref. 7; ABG73380).
FT   CONFLICT    139    140       GN -> DG (in Ref. 1; AAB59375).
FT   CONFLICT    174    174       T -> H (in Ref. 4; AAA51546).
FT   CONFLICT    229    229       E -> D (in Ref. 4; AAA51546).
FT   CONFLICT    273    273       T -> N (in Ref. 1; AAB59375).
FT   CONFLICT    280    280       D -> G (in Ref. 7; ABG73380).
FT   CONFLICT    326    326       V -> I (in Ref. 3; CAA25838).
FT   CONFLICT    410    410       G -> L (in Ref. 24; AA sequence).
FT   CONFLICT    414    414       N -> S (in Ref. 24; AA sequence).
FT   TURN         48     50
FT   HELIX        51     68
FT   STRAND       70     72
FT   STRAND       74     76
FT   HELIX        78     89
FT   HELIX        94    103
FT   TURN        108    110
FT   HELIX       113    127
FT   STRAND      137    145
FT   STRAND      146    148
FT   HELIX       152    159
FT   TURN        160    162
FT   STRAND      165    169
FT   STRAND      171    173
FT   HELIX       174    188
FT   TURN        189    191
FT   STRAND      206    215
FT   STRAND      218    220
FT   HELIX       224    226
FT   STRAND      228    235
FT   STRAND      238    256
FT   TURN        257    260
FT   STRAND      261    268
FT   TURN        269    271
FT   STRAND      272    279
FT   STRAND      280    282
FT   HELIX       284    290
FT   HELIX       293    301
FT   STRAND      306    313
FT   STRAND      315    322
FT   HELIX       323    329
FT   HELIX       334    336
FT   STRAND      337    340
FT   TURN        343    345
FT   STRAND      346    349
FT   STRAND      355    364
FT   STRAND      366    371
FT   HELIX       374    376
FT   STRAND      379    383
FT   STRAND      387    389
FT   STRAND      394    400
FT   TURN        401    403
FT   STRAND      406    413
SQ   SEQUENCE   418 AA;  46737 MW;  7016555F273B7F16 CRC64;
     MPSSVSWGIL LLAGLCCLVP VSLAEDPQGD AAQKTDTSHH DQDHPTFNKI TPNLAEFAFS
     LYRQLAHQSN STNIFFSPVS IATAFAMLSL GTKADTHDEI LEGLNFNLTE IPEAQIHEGF
     QELLRTLNQP DSQLQLTTGN GLFLSEGLKL VDKFLEDVKK LYHSEAFTVN FGDTEEAKKQ
     INDYVEKGTQ GKIVDLVKEL DRDTVFALVN YIFFKGKWER PFEVKDTEEE DFHVDQVTTV
     KVPMMKRLGM FNIQHCKKLS SWVLLMKYLG NATAIFFLPD EGKLQHLENE LTHDIITKFL
     ENEDRRSASL HLPKLSITGT YDLKSVLGQL GITKVFSNGA DLSGVTEEAP LKLSKAVHKA
     VLTIDEKGTE AAGAMFLEAI PMSIPPEVKF NKPFVFLMIE QNTKSPLFMG KVVNPTQK
//